

Cook, L.
09/627383

09/627383

L1 **FILE 'REGISTRY' ENTERED AT 15:39:03 ON 07 JUN 2002**
28 S LEPRAS/SQSP

Seg. 1D 1

L2 **FILE 'HCAPLUS' ENTERED AT 15:40:09 ON 07 JUN 2002**
23 S L1

L2 ANSWER 1 OF 23 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2001:872087 HCAPLUS
DOCUMENT NUMBER: 136:227947
TITLE: Nucleic acids and their encoded polypeptides
from human tissues
INVENTOR(S): Tang, Y. Tom; Liu, Chenghua; Drmanac, Radoje T.
PATENT ASSIGNEE(S): Hyseq, Inc., USA
SOURCE: PCT Int. Appl., 831 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 65
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001088088	A2	20011122	WO 2001-XC14827	20010516
W: AE, AG, AL, AM; AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
WO 2001088088	A2	20011122	WO 2001-US14827	20010516
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: US 2000-577408 A 20000518
WO 2001-US14827 W 20010516

AB The present invention provides a collection or library of 8051 nucleic acid contig sequences assembled from expressed sequence tag or cDNA libraries isolated mainly by sequencing by hybridization (SBH), std. PCR, Sanger sequencing techniques, and in some cases, sequences obtained from one or more public databases. The cDNA libraries are from human tissue sources and nearest neighbor sequence homologies are provided. The invention also relates to the proteins encoded by such polynucleotides, along with therapeutic, diagnostic and research utilities for these polynucleotides and proteins. [This abstr. record is one of four records for this

document necessitated by the large no. of index entries required to fully index the document and publication system constraints.].

IT 403520-71-8 403546-70-3

RL: ANT (Analyte); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(amino acid sequence; nucleic acids and their encoded polypeptides from human tissues)

L2 ANSWER 2 OF 23 HCAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:798430 HCAPLUS

DOCUMENT NUMBER: 135:353807

TITLE: Propionibacterium acnes nucleic acids and proteins useful for therapy and diagnosis of acne vulgaris

INVENTOR(S): Skeiky, Yasir A. W.; Persing, David H.; Mitcham, Jennifer L.; Wang, Siqing Steven; Bhatia, Ajay; L'Maisonneuve, Jean-Francois; Zhang, Yanni; Jen, Shyian; Carter, Darrick

PATENT ASSIGNEE(S): Corixa Corporation, USA

SOURCE: PCT Int. Appl., 1069 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 6

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001081581	A2	20011101	WO 2001-US12865	20010420
WO 2001081581	A3	20020314		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
WO 2001081581	A2	20011101	WO 2001-XA12865	20010420
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
WO 2001081581	A2	20011101	WO 2001-XB12865	20010420
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,				

09/627383

LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO,
NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT,
UA, UG, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ,
TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH,
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE,
TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD,
TG

WO 2001081581 A2 20011101 WO 2001-XC12865 20010420

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE,
GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO,
NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT,
UA, UG, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ,
TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH,
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE,
TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD,
TG

WO 2001081581 A2 20011101 WO 2001-XD12865 20010420

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE,
GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO,
NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT,
UA, UG, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ,
TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH,
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE,
TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD,
TG

WO 2001081581 A2 20011101 WO 2001-XE12865 20010420

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE,
GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO,
NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT,
UA, UG, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ,
TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH,
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE,
TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD,
TG

PRIORITY APPLN. INFO.:

US 2000-199047P P 20000421
US 2000-208841P P 20000602
US 2000-216747P P 20000707
WO 2001-US12865 W 20010420

AB Compns. and methods for the therapy and diagnosis of acne vulgaris and other related conditions are disclosed. Compns. may comprise one or more Propionibacterium acnes proteins, immunogenic portions thereof, or polynucleotides that encode such portions. Thus, overlapping clones representing approx. 8.6 full-length genome equiv. from a P. acnes genomic library were aligned to form 299 linear contigs. These 299 contigs represent a total assembled length of about 2,656,860 nucleotides covering >90% of the P. acnes genome. Six-frame translation is performed in order to predict 28,913 open reading frames encoding P. acnes polypeptide sequences. gtoreq.50

amino acids in length. A therapeutic compn. may also comprise an antibody that binds a *P. acnes* protein, antigen-presenting cells that express a *P. acnes* protein, or a T cell that is specific for cells expressing such a protein. Such compns. may be used, for example, for the prevention and/or treatment of acne. [This abstr. record is the first of six records for this document necessitated by the large no. of index entries required to fully index the document and publication system constraints.].

IT 371995-57-2

RL: ANT (Analyte); BOC (Biological occurrence); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence); USES (Uses)

(amino acid sequence; *Propionibacterium acnes* nucleic acids and proteins useful for therapy and diagnosis of acne vulgaris)

L2 ANSWER 3 OF 23 HCPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:781083 HCPLUS

DOCUMENT NUMBER: 135:353783

TITLE: Human nucleic acids and their encoded polypeptides

INVENTOR(S): Tang, Y. Tom; Liu, Chenghua; Drmanac, Radoje T.

PATENT ASSIGNEE(S): Hyseq, Inc., USA

SOURCE: PCT Int. Appl., 765 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 65

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001079449	A2	20011025	WO 2001-US8656	20010416
WO 2001079449	A3	20020328		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
PRIORITY APPLN. INFO.:			US 2000-552929	A 20000418
			US 2001-770160	A 20010126

AB The present invention provides 5497 novel nucleic acids, 5497 novel polypeptide sequences encoded by these nucleic acids, and their uses for diagnostic, therapeutic, and research purposes. A collection or library of the novel nucleic acid sequences were assembled from expressed sequence tags (ESTs) isolated mainly by sequencing by hybridization, and in some cases, sequences obtained from one or more public databases. Contigs were assembled using the EST sequence as a seed. Then a recursive algorithm was used to extend the seed EST into an extended assemblage, by pulling addnl. sequences from different databases that belong to this assemblage. [This abstr. record is one of two records for this document

09/627383

necessitated by the large no. of index entries required to fully index the document and publication system constraints.].

IT 369659-63-2P

RL: ANT (Analyte); BOC (Biological occurrence); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); BUU (Biological use, unclassified); PRP (Properties); ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence); PREP (Preparation); USES (Uses)

(amino acid sequence; human nucleic acids and their encoded polypeptides)

L2 ANSWER 4 OF 23 HCPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:545709 HCPLUS

DOCUMENT NUMBER: 135:148240

TITLE: Human nucleic acids and polypeptides

INVENTOR(S): Tang, Y. Tom; Liu, Chenghua; Asundi, Vinod; Chen, Rui-hong; Ma, Yunqing; Qian, Xiaohong B.; Ren, Feiyan; Wang, Dunrui; Wang, Jian-rui; Wang, Zhiwei; Wehrman, Tom; Xu, Chongjun; Xue, Aidong J.; Yang, Yonghong; Zhang, Jie; Zhao, Qing A.; Zhou, Ping; Goodrich, Ryle; Drmanac, Radoje T.

PATENT ASSIGNEE(S): Hyseq, Inc., USA; et al.

SOURCE: PCT Int. Appl., 10078 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 65

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001053312	A1	20010726	WO 2000-US34263	20001226
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2001025965	A5	20010731	AU 2001-25965	20001222
PRIORITY APPLN. INFO.:			US 2000-488725	A 20000121
			US 2000-552317	A 20000425
			US 2000-598042	A 20000709
			US 2000-620312	A 20000719
			US 2000-653450	A 20000803
			US 2000-662191	A 20000915
			US 2000-693036	A 20001019
			US 2000-727344	A 20001129
			US 1999-471275	A 19991223
			WO 2000-US35190	W 20001222

AB The present invention provides 1768 novel nucleic acids, novel polypeptide sequences encoded by these nucleic acids, and uses thereof. A plurality of novel nucleic acids were obtained from cDNA libraries prep'd. from various human tissues and in some cases from a

genomic library derived from human chromosomes using std. PCR, sequencing by hybridization (SBH) sequence signature anal., and Sanger sequencing techniques. The contigs or nucleic acids of the present invention were assembled using an EST sequence as a seed, with a recursive algorithm used to extend the seed EST into an extended assemblage by pulling addnl. sequences from different databases that belong to this assemblage. Full-length gene cDNA sequences and their corresponding protein sequences were generated from the assemblage.

IT 352374-90-4 352374-91-5 352374-92-6

RL: ANT (Analyte); BOC (Biological occurrence); BSU (Biological study, unclassified); BUU (Biological use, unclassified); PRP (Properties); ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence); USES (Uses)

(amino acid sequence; human nucleic acids and polypeptides)

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 5 OF 23 HCPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:241691 HCPLUS

DOCUMENT NUMBER: 134:261275

TITLE: Use of a BMP protein receptor complex for screening bone metabolism actives and cells co-transfected with a type II BMP receptor and type I BMP receptor

INVENTOR(S): Rosenbaum, Jan Susan

PATENT ASSIGNEE(S): The Procter & Gamble Company, USA

SOURCE: U.S., 85 pp., Cont.-in-part of U.S. Ser. No. 334,178, abandoned.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6210899	B1	20010403	US 1995-462467	19950605
WO 9614579	A1	19960517	WO 1995-US14027	19951030
	W: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KG, KP, KR, KZ, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TT, UA, UZ, VN RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
AU 9539713	A1	19960531	AU 1995-39713	19951030
AU 710559	B2	19990923		
EP 789844	A1	19970820	EP 1995-937676	19951030
EP 789844	B1	20020206		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE			
JP 10510047	T2	19980929	JP 1995-515373	19951030
AT 213064	E	20020215	AT 1995-937676	19951030
PRIORITY APPLN. INFO.:			US 1994-334178	B2 19941104
			US 1995-462467	A 19950605
			WO 1995-US14027	W 19951030

AB The present invention relates to a method for detg. whether a compd.

is capable of binding to a BMP receptor kinase protein complex. The invention further relates to a method for detg. the concn. of a BMP receptor ligand in a clin. sample. The invention also relates to a host cell co-transfected with an expression vector comprising a DNA sequence that codes for the BMP receptor kinase protein BRK-3 and an expression vector comprising a DNA sequence that codes for a BMP type I receptor kinase protein. The invention further relates to a host cell co-transfected with an expression vector comprising a DNA sequence that codes for a sol. or incomplete BMP type I receptor kinase protein and a sol. or incomplete BMP receptor kinase protein BRK-3. The invention further relates to a method for detg. whether a test compd. produces a signal upon binding to a BMP receptor protein complex.

IT 332001-59-9P 332001-60-2P

RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(amino acid sequence; use of BMP protein receptor complex for screening bone metab. actives and cells co-transfected with type II BMP receptor and type I BMP receptor)

REFERENCE COUNT: 66 THERE ARE 66 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 6 OF 23 HCPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:208400 HCPLUS

DOCUMENT NUMBER: 134:248841

TITLE: Crystalline three-dimensional structure of a metallo .beta.-lactamase IMP-1 from *Pseudomonas aeruginosa* and its complex with the inhibitor SB-252619, and applications to drug design

INVENTOR(S): Abdel-Meguid, Sherin S.; Concha, Nestor O.

PATENT ASSIGNEE(S): SmithKline Beecham Corporation, USA

SOURCE: PCT Int. Appl., 243 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001019971	A1	20010322	WO 2000-US25340	20000915
W: CA, JP, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				

PRIORITY APPLN. INFO.: US 1999-154749P P 19990917

AB Native crystal structure of a novel *Pseudomonas aeruginosa* metallo .beta.-lactamase IMP-1 and crystal structure of the *P. aeruginosa* metallo .beta.-lactamase IMP-1 complexed with the inhibitor SB-252619 are disclosed. The invention provides direct information on the specific role of the residues in the active site responsible for the binding of inhibitors, substrates and substrate analogs. This information could be used in search for new antibacterial drugs and in designing drugs useful for inhibiting the *P. aeruginosa* .beta.-lactamase IMP-1.

IT 331287-05-9

RL: PRP (Properties)

(unclaimed protein sequence; cryst. three-dimensional structure of a metallo .beta.-lactamase IMP-1 from *Pseudomonas aeruginosa* and its complex with the inhibitor SB-252619, and applications to drug design)

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 7 OF 23 HCPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 2001:125385 HCPLUS
 DOCUMENT NUMBER: 135:15597
 TITLE: Molecular and functional characterization of a family of rat brain T-type calcium channels
 AUTHOR(S): McRory, John E.; Santi, Celia M.; Hamming, Kevin S. C.; Mezeyova, Janette; Sutton, Kathy G.; Baillie, David L.; Stea, Anthony; Snutch, Terrance P.
 CORPORATE SOURCE: Biotechnology Laboratory, University of British Columbia, Vancouver, BC, V6T 1Z3, Can.
 SOURCE: Journal of Biological Chemistry (2001), 276(6), 3999-4011
 CODEN: JBCHA3; ISSN: 0021-9258
 PUBLISHER: American Society for Biochemistry and Molecular Biology

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Voltage-gated calcium channels represent a heterogeneous family of calcium-selective channels that can be distinguished by their mol., electrophysiol., and pharmacol. characteristics. We report here the mol. cloning and functional expression of three members of the low voltage-activated calcium channel family from rat brain (.alpha.1G, .alpha.1H, and .alpha.1I). Northern blot and reverse transcriptase-polymerase chain reaction analyses show .alpha.1G, .alpha.1H, and .alpha.1I to be expressed throughout the newborn and juvenile rat brain. In contrast, while .alpha.1G and .alpha.1H mRNA are expressed in all regions in adult rat brain, .alpha.1I mRNA expression is restricted to the striatum. Expression of .alpha.1G, .alpha.1H, and .alpha.1I subunits in HEK293 cells resulted in calcium currents with typical T-type channel characteristics: low voltage activation, neg. steady-state inactivation, strongly voltage-dependent activation and inactivation, and slow deactivation. In addn., the direct electrophysiol. comparison of .alpha.1G, .alpha.1H, and .alpha.1I under identical recording conditions also identified unique characteristics including activation and inactivation kinetics and permeability to divalent cations. Simulation of .alpha.1G, .alpha.1H, and .alpha.1I T-type channels in a thalamic neuron model cell produced unique firing patterns (burst vs. tonic) typical of different brain nuclei and suggests that the three channel types make distinct contributions to neuronal physiol.

IT 342874-40-2

RL: BAC (Biological activity or effector, except adverse); BOC (Biological occurrence); BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); OCCU (Occurrence); PROC (Process)
 (amino acid sequence; cloning, sequence and characterization of a family of rat brain T-type calcium channels)

REFERENCE COUNT: 58 THERE ARE 58 CITED REFERENCES AVAILABLE

09/627383

FOR THIS RECORD. ALL CITATIONS AVAILABLE
IN THE RE FORMAT

L2 ANSWER 8 OF 23 HCPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2001:106055 HCPLUS
DOCUMENT NUMBER: 134:188985
TITLE: Human expressed sequence tags and primers for
synthesizing full-length cDNAs
INVENTOR(S): Ota, Toshio; Isogai, Takao; Nishikawa, Tetsuo;
Hayashi, Kohji; Saito, Kaoru; Yamamoto, Junichi;
Ishii, Shizuko; Sugiyama, Tomoyasu; Wakamatsu,
Ai; Nagai, Keiichi; Otsuki, Tetsuji
PATENT ASSIGNEE(S): Helix Research Institute, Japan
SOURCE: Eur. Pat. Appl., 2527 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 9
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1074617	A2	20010207	EP 2000-116126	20000728
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
EP 1205549	A1	20020515	EP 2000-948282	20000728
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL			
PRIORITY APPLN. INFO.:			JP 1999-248036	A 19990729
			JP 1999-300253	A 19990827
			JP 2000-118776	A 20000111
			JP 2000-183767	A 20000502
			JP 2000-241899	A 20000609
			US 1999-159590P	P 19991018
			US 2000-183322P	P 20000217
			WO 2000-JP5065	W 20000728

AB Primers for synthesizing full-length cDNAs and their use are provided. The invention provides 5'-end sequences for 5602 partial cDNA sequences (expressed sequence tags, ESTs) and 3'-end sequences for 4970 of these clones. Furthermore, primers for synthesizing the full-length cDNA have been provided to clarify the function of the protein encoded by the cDNA. The full-length cDNA sequences of the present invention contg. the translation start site provides information useful for analyzing the functions of the proteins. Tissue- and cell-specific expression patterns are also provided. [This abstr. record is one of 6 records for this patent necessitated by the large no. of index entries required to fully index the document and publication system constraints.]
IT 326928-35-2, Protein (human clone PLACE1004777)
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(amino acid sequence; human expressed sequence tags and primers for synthesizing full-length cDNAs)

L2 ANSWER 9 OF 23 HCPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2001:101181 HCPLUS
DOCUMENT NUMBER: 134:159864
TITLE: Affinity fluorescent proteins and uses for

09/627383

INVENTOR(S): ligand detection
Matsudaira, Paul T.; Ehrlich, Daniel J.; Zhong,
Qiuwei; Freyson, Yelena
PATENT ASSIGNEE(S): Whitehead Institute for Biomedical Research, USA
SOURCE: PCT Int. Appl., 44 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001009177	A2	20010208	WO 2000-US20619	20000728
W: CA, JP				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				

PRIORITY APPLN. INFO.: US 1999-146438P P 19990729

AB The present invention is related to an affinity fluorescent protein (aFP) comprising a modified fluorescent protein or mol. which comprises a heterologous amino acid sequence, thereby introducing a ligand-activated protein binding site. The modified fluorescent protein displays an altered spectral property when the binding site is engaged with ligand relative to the spectral property displayed when the binding site is not engaged by ligand. The hexapeptide Leu-Glu-Pro-Arg-Ala-Ser which contains 3 restriction enzyme sites (XhoI-AvrI-NheI) is useful for identifying fluorescent insensitive sites in the green fluorescent protein (GFP). An epitope from hemagglutinin (HA tag comprising Tyr-Pro-Tyr-Asp-Val-Pro-Asp-Tyr-Ala) that is recognized by the monoclonal antibody 12CA5 is inserted into between residues Gln157-Lys158 and/or Glu172-Asp173 and/or at the C-terminus of GFP; a Ser-147-Pro substitution is introduced into GFP for improved stability. The present invention also relates to an aFP expression cassette comprising a modified fluorescent protein nucleic acid sequence operatively linked to expression control sequences, wherein the modified fluorescent protein sequence comprises a recombinant peptide which comprises restriction endonuclease sites. The present invention also relates to a method of detecting the presence of a target ligand in a mixt. of macromols. Also encompassed by the present invention is a method of detecting the occurrence of a target ligand in a cell (e.g., a macrophage, a yeast cell).

IT 324745-26-8
RL: BUU (Biological use, unclassified); BIOL (Biological study);
USES (Uses)
(affinity ligand; affinity fluorescent proteins and uses for
ligand detection)

L2 ANSWER 10 OF 23 HCPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2001:56134 HCPLUS
DOCUMENT NUMBER: 135:176236
TITLE: Cloning and structural characterization of
ECTACC, a new member of the transforming acidic
coiled coil (TACC) gene family: cDNA sequence
and expression analysis in human microvascular
endothelial cells
AUTHOR(S): Pu, Jeffrey J.; Li, Chaoyang; Rodriguez,
Marilis; Banerjee, Debendranath

CORPORATE SOURCE: Department of Membrane Biochemistry II, The
 Lindsley F. Kimball Research Institute, New York
 Blood Center, New York, NY, 10021, USA

SOURCE: Cytokine (2001), 13(3), 129-137
 CODEN: CYTIE9; ISSN: 1043-4666

PUBLISHER: Academic Press

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Erythropoietin (Epo) transduces mitogenic and chemoattractant signals to human endothelial cells. Identifications of Epo-responsive genes are important for understanding the mol. nature of Epo signaling in endothelial cells. The effects of Epo on differential expression of various genes were examd. in human microvascular endothelial cells (HMVEC) by differential display reverse transcriptase polymerase chain reaction (RT-PCR). In the current study we obtained from Epo-treated HMVEC a cDNA fragment with characteristics of the 3' end of mRNA. Using the cDNA fragment, we then selectively isolated a full-length clone by screening an unamplified endothelial cell cDNA library followed by 5' rapid amplification of cDNA ends by polymerase chain reaction (RACE-PCR). The nucleotide sequence of the longest cDNA revealed an open reading frame of 3311 nucleotides that encodes a protein consisting of .apprx.906 amino acids with a predicted MW of .apprx.100 kDa. The nucleotide sequence of the cDNA is nearly identical to that of transforming acidic coiled coil-contg. (TACC2) and anti-zuai-1 (AZU-1) cDNA clones except at the 5'- and 3'-ends. Northern blot anal. showed an increase in endothelial-TACC-related mRNA levels in Epo-treated cells in comparison to that of the control cells. Endothelial-TACC-related mRNA was highly expressed in heart and skeletal muscle tissue. Placenta and brain tissue exhibited low levels of expression of endothelial-TACC-related gene. Southern blot anal. of genomic DNA from somatic cell hybrids showed that endothelial-TACC-related cDNA maps to chromosome 10. Immunofluorescence microscopy and the occurrence of several putative phosphorylation and SH3 binding sites on the deduced protein suggest that endothelial-TACC-related protein may be involved in Epo signaling cascades in endothelial cells. (c) 2001 Academic Press.

IT 355157-34-5, Protein ECTACC (human)
 RL: BPR (Biological process); BSU (Biological study, unclassified);
 PRP (Properties); BIOL (Biological study); PROC (Process)
 (amino acid sequence; cloning and structural characterization of
 ECTACC of human, a new member of the transforming acidic coiled
 coil (TACC) gene family)

REFERENCE COUNT: 37 THERE ARE 37 CITED REFERENCES AVAILABLE
 FOR THIS RECORD. ALL CITATIONS AVAILABLE
 IN THE RE FORMAT

L2 ANSWER 11 OF 23 HCPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:31638 HCPLUS

DOCUMENT NUMBER: 134:111253

TITLE: Novel mammalian calcium channels and related
 probes, cell lines and methods

INVENTOR(S): Snutch, Terrance P.; Baillie, David L.

PATENT ASSIGNEE(S): Neuromed Technologies, Inc., Can.

SOURCE: PCT Int. Appl., 103 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

09/627383

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001002561	A2	20010111	WO 2000-CA794	20000704
WO 2001002561	A3	20010628		
W: AU, CA, IL, JP, NO, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 1190053	A2	20020327	EP 2000-945479	20000704
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
PRIORITY APPLN. INFO.:			US 1999-346794	A 19990702
			WO 2000-CA794	W 20000704

AB Sequences and partial sequences for three types of mammalian (human and rat sequences identified) T-type calcium channel subunits which we have labeled as the .alpha.1G, .alpha.1H and .alpha.1I subunits are provided. Knowledge of the sequence of these calcium channels permits the localization and recovery of the complete sequence from human cells, and the development of cell lines which express the novel calcium channels of the invention. These cells may be used for identifying compds. capable of acting as agonists or antagonists to the calcium channels.

IT 319502-44-8

RL: PRP (Properties)

(unclaimed protein sequence; novel mammalian calcium channels and related probes, cell lines and methods)

L2 ANSWER 12 OF 23 HCPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:12616 HCPLUS

DOCUMENT NUMBER: 134:82484

TITLE: Fanconi anemia protein interacting proteins FANCIP2 and FANCIP3 and cDNAs and methods for diagnosis and treatment of diseases

INVENTOR(S): Gross, Hans Joachim; Reuter, Tanja; Hanenberg, Helmut; Herterich, Sabine; Wagner, Matthias

PATENT ASSIGNEE(S): Multigene Biotech GmbH, Germany

SOURCE: PCT Int. Appl., 60 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001000822	A2	20010104	WO 2000-EP5878	20000626
WO 2001000822	A3	20010705		
W: AE, AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CR, CU, CZ, DM, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KP, KR, KZ, LC, LK, LR, LT, LV, MA, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, TZ, UA, US, UZ, VN, YU, ZA				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
DE 19929887	A1	20010111	DE 1999-19929887	19990629
EP 1194547	A2	20020410	EP 2000-943885	20000626

Searcher : Shears 308-4994

09/627383

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC,
PT, IE, SI, LT, LV, FI, RO

PRIORITY APPLN. INFO.: DE 1999-19929887 A 19990629
WO 2000-EP5878 W 20000626

AB The invention relates to cDNA sequences encoding proteins FANCIP2 and FANCIP3, which interact with the Fanconi anemia complementation group A (FANCA) protein, and the corresponding encoded proteins. The invention also relates to antibodies directed to said proteins, to FANCIP2- or FANCIP3-transgenic organisms and cells, and to the use of FANCIP2 and FANCIP3 for effector screening, and to the pharmaceutical application of the inventive nucleic acids, proteins and antibodies.

IT 316927-56-7

RL: PRP (Properties)

(unclaimed protein sequence; fanconi anemia protein interacting proteins FANCIP2 and FANCIP3 and cDNAs and methods for diagnosis and treatment of diseases)

L2 ANSWER 13 OF 23 HCPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2000:540554 HCPLUS

DOCUMENT NUMBER: 133:130477

TITLE: The genome sequence of the plant pathogen
Xylella fastidiosa

AUTHOR(S): Simpson, A. J. G.; Reinach, F. C.; Arruda, P.; Abreu, F. A.; Acencio, M.; Alvarenga, R.; Alves, L. M. C.; Araya, J. E.; Bala, G. S.; Baptista, C. S.; Barros, M. H.; Bonaccorsi, E. D.; Bordin, S.; Bove, J. M.; Briones, M. R. S.; Bueno, M. R. P.; Camargo, A. A.; Camargo, L. E. A.; Carraro, D. M.; Carrer, H.; Colauto, N. B.; Colombo, C.; Costa, F. F.; Costa, M. C. R.; Costa-Neto, C. M.; Coutinho, L. L.; Cristofani, M.; Dias-Neto, E.; Docena, C.; El-Dorry, H.; Facincani, A. P.; Ferreira, A. J. S.; Ferreira, V. C. A.; Ferro, J. A.; Fraga, J. S.; Franca, S. C.; Franco, M. C.; Frohme, M.; Furtan, L. R.; Garnier, M.; Goldman, G. H.; Goldman, M. H. S.; Gomes, S. L.; Gruber, A.; Ho, P. L.; Hoheisel, J. D.; Junqueira, M. L.; Kemper, E. L.; Kitajima, J. P.; Kreiger, J. E.; Duramae, E. E.; Laigret, F.; Lambals, M. R.; Lette, L. C. C.; Lemos, E. G. M.; Lemos, M. V. F.; Lopes, S. A.; Lopes, C. R.; Machado, J. A.; Machado, M. A.; Madeira, A. M. B. N.; Madeira, H. M. F.; Marino, C. L.; Marques, M. V.; Martins, E. A. L.; Martins, E. M. F.; Matsukuma, A. Y.; Menck, C. F. M.; Miracca, E. C.; Miyaki, C. Y.; Monteiro-Vitorello, C. B.; Moon, D. H.; Nagai, M. A.; Nascimento, A. L. T. O.; Netto, L. E. S.; Nhanl, A., Jr.; Nobrega, F. G.; Nunes, L. R.; Oliveira, M. A.; de Oliveira, M. C.; de Oliveira, R. C.; Palmieri, D. A.; Paris, A.; Peixoto, B. R.; Pereira, G. A. G.; Perelra, H. A.; Pesquero, J. B.; Quaggio, R. B.; Roberto, P. G.; Rodrigues, V.; Rosa, A. J. de M.; de Rosa, V. E., Jr.; de Sa, R. G.; Santelli, R. V.; Sawasaki, H. E.; da Silva, A. C. R.; da Silva, A. M.; da Silva, F. R.; Silva, W. A., Jr.; da

Silveira, J. F.; Silvestri, M. L. Z.; Siqueira, W. J.; de Souza, A. A.; de Souza, A. P.; Terenzi, M. F.; Truffi, D.; Tsai, S. M.; Tsuhako, M. H.; Vallada, H.; Van Sluys, M. A.; Verjovskii-Almeida, S.; Vettore, A. L.; Zago, M. A.; Zatz, M.; Meidanis, J.; Setubal, J. C.

CORPORATE SOURCE: Instituto Ludwig de Pesquisa sobre o Cancer, Sao Paulo, 01509-010, Brazil

SOURCE: Nature (London) (2000), 406(6792), 151-157
CODEN: NATUAS; ISSN: 0028-0836

PUBLISHER: Nature Publishing Group

DOCUMENT TYPE: Journal

LANGUAGE: English

AB *Xylella fastidiosa* is a fastidious, xylem-limited bacterium that causes a range of economically important plant diseases. The complete genome sequence of *X. fastidiosa* clone 9a5c, which causes citrus variegated chlorosis-a serious disease of orange trees, is reported. The genome comprises a 52.7% GC-rich 2,679,305-base-pair (bp) circular chromosome and two plasmids of 51,158 bp and 1,285 bp. Putative functions can be assigned to 47% of the 2904 predicted coding regions. Efficient metabolic functions are predicted, with sugars as the principal energy and carbon source, supporting existence in the nutrient-poor xylem sap. The mechanisms assocd. with pathogenicity and virulence involve toxins, antibiotics and ion sequestration systems, as well as bacterium-bacterium and bacterium-host interactions mediated by a range of proteins. Orthologs of some of these proteins have only been identified in animal and human pathogens; their presence in *X. fastidiosa* indicates that the mol. basis for bacterial pathogenicity is both conserved and independent of host. At least 83 genes are bacteriophage-derived and include virulence-assocd. genes from other bacteria, providing direct evidence of phage-mediated horizontal gene transfer.

IT 284706-28-1, Protein (*Xylella fastidiosa* gene XF1737)

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)

(amino acid sequence; genome sequence of the plant pathogen *Xylella fastidiosa*)

L2 ANSWER 14 OF 23 HCAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2000:246921 HCAPLUS

DOCUMENT NUMBER: 132:275067

TITLE: The genome sequence of *Drosophila melanogaster*

AUTHOR(S): Adams, Mark D.; Celniker, Susan E.; Holt, Robert A.; Evans, Cheryl A.; Gocayne, Jeannine D.; Amanatides, Peter G.; Scherer, Steven E.; Li, Peter W.; Hoskins, Roger A.; Galle, Richard F.; George, Reed A.; Lewis, Suzanna E.; Richards, Stephen; Ashburner, Michael; Henderson, Scott N.; Sutton, Granger G.; Wortman, Jennifer R.; Yandell, Mark D.; Zhang, Qing; Chen, Lin X.; Brandon, Rhonda C.; Rogers, Yu-Hui C.; Blazej, Robert G.; Champe, Mark; Pfeiffer, Barret D.; Wan, Kenneth H.; Doyle, Clare; Baxter, Evan G.; Helt, Gregg; Nelson, Catherine R.; Miklos, George L. Gabor; Abril, Josep F.; Agbayani, Anna; An, Hui-Jin; Andrews-Pfannkoch, Cynthia; Baldwin, Danita; Ballew, Richard M.; Basu,

09/627383

Anand; Baxendale, James; Bayraktaroglu, Leyla;
Beasley, Ellen M.; Beeson, Karen Y.; Benos, P.
V.; Berman, Benjamin P.; Bhandari, Deepali;
Bolshakov, Slava; Borkova, Dana; Botchan,
Michael R.; Bouck, John; Brokstein, Peter;
Brottier, Phillip; Burtis, Kenneth C.; Busam,
Dana A.; Butler, Heather; Cadieu, Edouard;
Center, Angela; Chandra, Ishwar; Cherry, J.
Michael; Cawley, Simon; Dahlke, Carl; Davenport,
Lionel B.; Davies, Peter; De Pablos, Beatriz;
Delcher, Arthur; Deng, Zuoming; Mays, Anne
Deslattes; Dew, Ian; Dietz, Suzanne M.; Dodson,
Kristina; Doup, Lisa E.; Downes, Michael;
Dugan-Rocha, Shannon; Dunkov, Boris C.; Dunn,
Patrick; Durbin, Kenneth J.; Evangelista, Carlos
C.; Ferraz, Concepcion; Ferriera, Steven;
Fleischmann, Wolfgang; Foster, Carl; Gabrielian,
Andrei E.; Garg, Neha S.; Gelbart, William M.;
Glasser, Ken; Glodek, Anna; Gong, Fangcheng;
Gorrell, J. Harley; Gu, Zhiping; Guan, Ping;
Harris, Michael; Harris, Nomi L.; Harvey, Damon;
Heiman, Thomas J.; Hernandez, Judith R.; Houck,
Jarrett; Hostin, Damon; Houston, Kathryn A.;
Howland, Timothy J.; Wei, Ming-Hui; Ibegwam,
Chinyere; Jalali, Mena; Kalush, Francis; Karpen,
Gary H.; Ke, Zhaoxi; Kennison, James A.;
Ketchum, Karen A.; Kimmel, Bruce E.; Kodira,
Chinnappa D.; Kraft, Cheryl; Kravitz, Saul;
Kulp, David; Lai, Zhongwu; Lasko, Paul; Lei,
Yiding; Levitsky, Alexander A.; Li, Jiayin; Li,
Zhenya; Liang, Yong; Lin, Xiaoying; Liu,
Xiangjun; Mattei, Bettina; McIntosh, Tina C.;
McLeod, Michael P.; McPherson, Duncan; Merkulov,
Gennady; Milshina, Natalia V.; Mobarry, Clark;
Morris, Joe; Moshrefi, Ali; Mount, Stephen M.;
Moy, Mee; Murphy, Brian; Murphy, Lee; Muzny,
Donna M.; Nelson, David L.; Nelson, David R.;
Nelson, Keith A.; Nixon, Katherine; Nusskern,
Deborah R.; Pacleb, Joanne M.; Palazzolo,
Michael; Pittman, Gjange S.; Pan, Sue; Pollard,
John; Puri, Vinita; Reese, Martin G.; Reinert,
Knut; Remington, Karin; Saunders, Robert D. C.;
Scheeler, Frederick; Shen, Hua; Shue, Bixiang
Christopher; Siden-Kiamos, Inga; Simpson,
Michael; Skupski, Marian P.; Smith, Tom; Spier,
Eugene; Spradling, Allan C.; Stapleton, Mark;
Strong, Renee; Sun, Eric; Svirskas, Robert;
Tector, Cyndee; Turner, Russell; Venter, Eli;
Wang, Aihui H.; Wang, Xin; Wang, Zhen-Yuan;
Wassarman, David A.; Weinstock, George M.;
Weissenbach, Jean; Williams, Sherita M.;
Woodage, Trevor; Worley, Kim C.; Wu, David;
Yang, Song; Yao, Q. Alison; Ye, Jane; Yeh,
Ru-Fang; Zaveri, Jayshree S.; Zhan, Ming; Zhang,
Guangren; Zhao, Qi; Zheng, Liansheng; Zheng,
Xiangqun H.; Zhong, Fei N.; Zhong, Wenyan; Zhou,
Xiaojun; Zhu, Shiaoping; Zhu, Xiaohong; Smith,
Hamilton O.; Gibbs, Richard A.; Myers, Eugene

CORPORATE SOURCE: W.; Rubin, Gerald M.; Venter, J. Craig
 SOURCE: Celera Genomics, Rockville, MD, 20850, USA
 Science (Washington, D. C.) (2000), 287(5461),
 2185-2195
 CODEN: SCIEAS; ISSN: 0036-8075
 PUBLISHER: American Association for the Advancement of
 Science
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB The fly *Drosophila melanogaster* is one of the most intensively studied organisms in biol. and serves as a model system for the investigation of many developmental and cellular processes common to higher eukaryotes, including humans. The nucleotide sequence was detd. of nearly all of the .apprx.120-megabase euchromatic portion of the *Drosophila* genome using a whole-genome shotgun sequencing strategy supported by extensive clone-based sequence and a high-quality bacterial artificial chromosome phys. map. Efforts are under way to close the remaining gaps; however, the sequence is of sufficient accuracy and contiguity to be declared substantially complete and to support an initial anal. of genome structure and preliminary gene annotation and interpretation. The genome encodes .apprx.13,600 genes, somewhat fewer than the smaller *Caenorhabditis elegans* genome, but with comparable functional diversity. Access to supporting information on each gene is available through FlyBase at <http://flybase.bio.indiana.edu> and through Celera at www.celera.com; the sequences are deposited in GenBank with Accession Nos. AE002566-AE003403. [This abstr. record is one of 4 records for this document necessitated by the large no. of index entries required to fully index the document and publication system restraints.].

IT 263525-23-1
 RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
 (Biological study)
 (amino acid sequence; genome sequence of *Drosophila melanogaster*)

L2 ANSWER 15 OF 23 HCPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 2000:230405 HCPLUS
 DOCUMENT NUMBER: 132:304167
 TITLE: The genome sequence of *Drosophila melanogaster*
 AUTHOR(S): Adams, Mark D.; Celniker, Susan E.; Holt, Robert
 A.; Evans, Cheryl A.; Gocayne, Jeannine D.;
 Amanatides, Peter G.; Scherer, Steven E.; Li,
 Peter W.; Hoskins, Roger A.; Galle, Richard F.;
 George, Reed A.; Lewis, Suzanna E.; Richards,
 Stephen; Ashburner, Michael; Henderson, Scott
 N.; Sutton, Granger G.; Wortman, Jennifer R.;
 Yandell, Mark D.; Zhang, Qing; Chen, Lin X.;
 Brandon, Rhonda C.; Rogers, Yu-Hui C.; Blazej,
 Robert G.; Champe, Mark; Pfeiffer, Barret D.;
 Wan, Kenneth H.; Doyle, Clare; Baxter, Evan G.;
 Helt, Gregg; Nelson, Catherine R.; Miklos,
 George L. Gabor; Abril, Josep F.; Agbayani,
 Anna; An, Hui-Jin; Andrews-Pfannkoch, Cynthia;
 Baldwin, Danita; Ballew, Richard M.; Basu,
 Anand; Baxendale, James; Bayraktaroglu, Leyla;
 Beasley, Ellen M.; Beeson, Karen Y.; Benos, P.
 V.; Berman, Benjamin P.; Bhandari, Deepali;
 Bolshakov, Slava; Borkova, Dana; Botchan,
 Michael R.; Bouck, John; Brokstein, Peter;

09/627383

Brottier, Phillip; Burtis, Kenneth C.; Busam, Dana A.; Butler, Heather; Cadieu, Edouard; Center, Angela; Chandra, Ishwar; Cherry, J. Michael; Cawley, Simon; Dahlke, Carl; Davenport, Lionel B.; Davies, Peter; De Pablos, Beatriz; Delcher, Arthur; Deng, Zuoming; Mays, Anne Deslattes; Dew, Ian; Dietz, Suzanne M.; Dodson, Kristina; Doup, Lisa E.; Downes, Michael; Dugan-Rocha, Shannon; Dunkov, Boris C.; Dunn, Patrick; Durbin, Kenneth J.; Evangelista, Carlos C.; Ferraz, Concepcion; Ferriera, Steven; Fleischmann, Wolfgang; Foster, Carl; Gabrielian, Andrei E.; Garg, Neha S.; Gelbart, William M.; Glasser, Ken; Glodek, Anna; Gong, Fangcheng; Gorrell, J. Harley; Gu, Zhiping; Guan, Ping; Harris, Michael; Harris, Nomi L.; Harvey, Damon; Heiman, Thomas J.; Hernandez, Judith R.; Houck, Jarrett; Hostin, Damon; Houston, Kathryn A.; Howland, Timothy J.; Wei, Ming-Hui; Ibegwam, Chinyere; Jalali, Mena; Kalush, Francis; Karpen, Gary H.; Ke, Zhaoxi; Kennison, James A.; Ketchum, Karen A.; Kimmel, Bruce E.; Kodira, Chinnappa D.; Kraft, Cheryl; Kravitz, Saul; Kulp, David; Lai, Zhongwu; Lasko, Paul; Lei, Yiding; Levitsky, Alexander A.; Li, Jiayin; Li, Zhenya; Liang, Yong; Lin, Xiaoying; Liu, Xiangjun; Mattei, Bettina; McIntosh, Tina C.; McLleod, Michael P.; McPherson, Duncan; Merkulov, Gennady; Milshina, Natalia V.; Mobarry, Clark; Morris, Joe; Moshrefi, Ali; Mount, Stephen M.; Moy, Mee; Murphy, Brian; Murphy, Lee; Muzny, Donna M.; Nelson, David L.; Nelson, David R.; Nelson, Keith A.; Nixon, Katherine; Nusskern, Deborah R.; Pacleb, Joanne M.; Palazzolo, Michael; Pittman, Gjange S.; Pan, Sue; Pollard, John; Puri, Vinita; Reese, Martin G.; Reinert, Knut; Remington, Karin; Saunders, Robert D. C.; Scheeler, Frederick; Shen, Hua; Shue, Bixiang Christopher; Siden-Kiamos, Inga; Simpson, Michael; Skupski, Marian P.; Smith, Tom; Spier, Eugene; Spradling, Allan C.; Stapleton, Mark; Strong, Renee; Sun, Eric; Svirskas, Robert; Tector, Cyndee; Turner, Russell; Venter, Eli; Wang, Aihui H.; Wang, Xin; Wang, Zhen-Yuan; Wassarman, David A.; Weinstock, George M.; Weissenbach, Jean; Williams, Sherita M.; Woodage, Trevor; Worley, Kim C.; Wu, David; Yang, Song; Yao, Q. Alison; Ye, Jane; Yeh, Ru-Fang; Zaveri, Jayshree S.; Zhan, Ming; Zhang, Guangren; Zhao, Qi; Zheng, Liansheng; Zheng, Xiangqun H.; Zhong, Fei N.; Zhong, Wenyan; Zhou, Xiaojun; Zhu, Shiaoping; Zhu, Xiaohong; Smith, Hamilton O.; Gibbs, Richard A.; Myers, Eugene W.; Rubin, Gerald M.; Venter, J. Craig Celera Genomics, Rockville, MD, 20850, USA Science (Washington, D. C.) (2000), 287(5461), 2185-2195 CODEN: SCIEAS; ISSN: 0036-8075

CORPORATE SOURCE:
SOURCE:

Searcher : Shears 308-4994

09/627383

PUBLISHER: American Association for the Advancement of
Science

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The fly *Drosophila melanogaster* is one of the most intensively studied organisms in biol. and serves as a model system for the investigation of many developmental and cellular processes common to higher eukaryotes, including humans. The nucleotide sequence was detd. of nearly all of the apprx.120-megabase euchromatic portion of the *Drosophila* genome using a whole-genome shotgun sequencing strategy supported by extensive clone-based sequence and a high-quality bacterial artificial chromosome phys. map. Efforts are under way to close the remaining gaps; however, the sequence is of sufficient accuracy and contiguity to be declared substantially complete and to support an initial anal. of genome structure and preliminary gene annotation and interpretation. The genome encodes apprx.13,600 genes, somewhat fewer than the smaller *Caenorhabditis elegans* genome, but with comparable functional diversity. Access to supporting information on each gene is available through FlyBase at <http://flybase.bio.indiana.edu> and through Celera at www.celera.com; the sequences are deposited in GenBank with Accession Nos. AE002566-AE003403. [This abstr. record is one of 4 records for this document necessitated by the large no. of index entries required to fully index the document and publication system constraints.].

IT 262988-39-6

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
(Biological study)

(amino acid sequence; genome sequence of *Drosophila melanogaster*)

REFERENCE COUNT: 89 THERE ARE 89 CITED REFERENCES AVAILABLE
FOR THIS RECORD. ALL CITATIONS AVAILABLE
IN THE RE FORMAT

L2 ANSWER 16 OF 23 HCPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2000:161309 HCPLUS

DOCUMENT NUMBER: 132:204089

TITLE: Protein and cDNA sequences encoding *Neisseria meningitidis* NMASP protein, and uses thereof in treating meningitis

INVENTOR(S): Jackson, W. James; Harris, Andrea M.

PATENT ASSIGNEE(S): Antex Biologics Inc., USA

SOURCE: PCT Int. Appl., 76 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000012535	A2	20000309	WO 1999-US19663	19990901
WO 2000012535	A3	20000608		
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE,			

09/627383

DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,
CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
US 2002018782 A1 20020214 US 1999-388089 19990831
AU 9957894 A1 20000321 AU 1999-57894 19990901
EP 1109454 A2 20010627 EP 1999-945257 19990901
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC,
PT, IE, SI, LT, LV, FI, RO
PRIORITY APPLN. INFO.: US 1998-98685P P 19980901
WO 1999-US19663 W 19990901

AB The invention discloses the *Neisseria meningitidis* NMASP protein and cDNA sequences, derivs. thereof (NMASP-derived polypeptides), and antibodies that specifically bind the NMASP protein and/or NMASP-derived polypeptides. The NMASP protein of the invention has limited similarity (36% sequence identity) to the DegP (HtrA) protein of *E. coli* and has not been previously identified in any *N. meningitidis*. Also disclosed are prophylactic or therapeutic compns., including immunogenic compns. like vaccines, comprising NMASP protein and/or a NMASP-derived polypeptide. The invention is particularly directed toward compns. for treating/preventing meningitis. The invention addnl. discloses methods of inducing an immune response to *N. meningitidis* and *N. meningitidis* NMASP protein and/or a NMASP-derived polypeptide in animals.

IT 260386-80-9P, Protein NMASP (*Neisseria meningitidis*)
RL: BOC (Biological occurrence); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); OCCU (Occurrence); PREP (Preparation); USES (Uses)
(amino acid sequence; protein and cDNA sequences encoding *Neisseria meningitidis* NMASP protein, and uses thereof in treating and diagnosing meningitis)

L2 ANSWER 17 OF 23 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2000:15224 HCAPLUS
DOCUMENT NUMBER: 132:74540
TITLE: Protein and cDNA sequences of human tumor suppressor proteins encoded by AZ-1 and AZ-2 genes, and uses thereof in the diagnosis, prevention, and/or treatment of breast cancer
INVENTOR(S): Chen, Huei Mei; Bissell, Mina
PATENT ASSIGNEE(S): USA
SOURCE: PCT Int. Appl., 120 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 20000000503	A1	20000106	WO 1999-US14482	19990625
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,				

09/627383

CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
AU 9948347 A1 20000117 AU 1999-48347 19990625
PRIORITY APPLN. INFO.: US 1998-90747P P 19980626
WO 1999-US14482 W 19990625

AB The invention provides protein and cDNA sequences of human tumor suppressor proteins encoded by AZ-1 and AZ-2 genes. Preferably, the invention relates to the tumor suppressor encoded by the AZ-1 gene and to the detection of its level in breast cells as a marker of malignancy progression and/or tumorigenic reversion. Thus, the invention also relates to the diagnosis, prevention, and/or treatment of breast cancer. The invention also concerns monoclonal or polyclonal antibodies specific to AZ-1, AZ-2 encoded protein and to AZ-1, or AZ-2 encoded protein homologs.

IT 253582-33-1P
RL: BAC (Biological activity or effector, except adverse); BOC (Biological occurrence); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); OCCU (Occurrence); PREP (Preparation); USES (Uses)
(amino acid sequence; protein and cDNA sequences of human tumor suppressor proteins encoded by AZ-1 and AZ-2 genes, and uses thereof in the diagnosis, prevention, and/or treatment of breast cancer)

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 18 OF 23 HCAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1999:762121 HCAPLUS

DOCUMENT NUMBER: 131:347336

TITLE: Genome sequence of the radioresistant bacterium Deinococcus radiodurans R1

AUTHOR(S): White, Owen; Eisen, Jonathan A.; Heidelberg, John F.; Hickey, Erin K.; Peterson, Jeremy D.; Dodson, Robert J.; Haft, Daniel H.; Gwinn, Michelle L.; Nelson, William C.; Richardson, Delwood L.; Moffat, Kelly S.; Qin, Haiying; Jiang, Lingxia; Pamphile, Wanda; Crosby, Marie; Shen, Mian; Vamathevan, Jessica J.; Lam, Peter; McDonald, Lisa; Utterback, Terry; Zalewski, Celeste; Makarova, Kira S.; Aravind, L.; Daly, Michael J.; Minton, Kenneth W.; Fleischmann, Robert D.; Ketchum, Karen A.; Nelson, Karen E.; Salzberg, Steven; Smith, Hamilton O.; Venter, J. Craig; Fraser, Claire M.

CORPORATE SOURCE: The Institute for Genomic Research, Rockville, MD, 20850, USA

SOURCE: Science (Washington, D. C.) (1999), 286(5444), 1571-1577

CODEN: SCIEAS; ISSN: 0036-8075

PUBLISHER: American Association for the Advancement of Science

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The complete genome sequence of the radiation-resistant bacterium Deinococcus radiodurans R1 is composed of two chromosomes (2,648,638 and 412,348 base pairs), a megaplasmid (177,466 base pairs), and a small plasmid (45,704 base pairs), yielding a total genome of

09/627383

3,284,156 base pairs. Multiple components distributed on the chromosomes and megaplasmid that contribute to the ability of *D. radiodurans* to survive under conditions of starvation, oxidative stress, and high amts. of DNA damage were identified. *Deinococcus radiodurans* represents an organism in which all systems for DNA repair, DNA damage export, desiccation and starvation recovery, and genetic redundancy are present in one cell.

IT 250313-43-0

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(amino acid sequence; genome sequence of the radioresistant bacterium *Deinococcus radiodurans* R1)

REFERENCE COUNT: 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 19 OF 23 HCPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1999:444338 HCPLUS

DOCUMENT NUMBER: 131:253834

TITLE: The Cloning and Developmental Expression of Unconventional Myosin IXA (MYO9A) a Gene in the Bardet-Biedl Syndrome (BBS4) Region at Chromosome 15q22-q23

AUTHOR(S): Gorman, Susan W.; Haider, Neena B.; Grieshammer, Uta; Swiderski, Ruth E.; Kim, Esther; Welch, Juliet W.; Searby, Charles; Leng, Song; Carmi, Rivka; Sheffield, Val C.; Duhl, David M.

CORPORATE SOURCE: Chiron Corporation, Emeryville, CA, 94608, USA

SOURCE: Genomics (1999), 59(2), 150-160

CODEN: GNMCEP; ISSN: 0888-7543

PUBLISHER: Academic Press

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Bardet-Biedl Syndrome (BBS) is a heterogeneous, autosomal recessive disorder characterized by mental retardation, obesity, retinitis pigmentosa, syndactyly and/or polydactyly, short stature, and hypogenitalism and is caused by mutations at a no. of distinct loci. Using a positional cloning approach for identifying the BBS4 (chromosome 15) gene, we identified and cloned an unconventional myosin gene, myosin IXA (HGMW-approved symbol MYO9A). Since mutations in unconventional myosins are known to cause several human diseases, and since mutations of unconventional myosin VIIa cause retinal degeneration, we evaluated myosin IXA as a candidate for BBS. We exploited PCR-based techniques to clone a 8473-nt cDNA for myosin IXA. A 7644-bp open reading frame predicts a protein with all the hallmarks of class IX unconventional myosins. Human Northern blot anal. and in situ hybridization of mouse embryos reveal that myosin IXA is expressed in many tissues consistent with BBS. Intron/exon boundaries were identified, and myosin IXA DNA and RNA from BBS4 patients were evaluated for mutation. (c) 1999 Academic Press.

IT 244613-54-5

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)

(amino acid sequence; cloning, cDNA sequence, and mRNA expression of unconventional myosin IXA gene (MYO9A), a gene in the Bardet-Biedl Syndrome (BBS4) region at chromosome 15q22-q23)

REFERENCE COUNT: 42 THERE ARE 42 CITED REFERENCES AVAILABLE

FOR THIS RECORD. ALL CITATIONS AVAILABLE
IN THE RE FORMAT

L2 ANSWER 20 OF 23 HCAPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 1999:271499 HCAPLUS
 DOCUMENT NUMBER: 130:292458
 TITLE: The amino acid and nucleic acid sequences of Myosin IXa and cyclic nucleotide gated channel and their uses in diagnosis and treatment of human diseases
 INVENTOR(S): Gorman, Susan W.; Welch, Julie; Duhl, David; Leng, Song; Adams, Arwen; Sheffield, Val; Chiu, Choi Ying
 PATENT ASSIGNEE(S): Chiron Corporation, USA
 SOURCE: PCT Int. Appl., 69 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9919489	A1	19990422	WO 1998-US21971	19981014
W: AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, CZ, DE, DE, DK, DK, EE, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9910986	A1	19990503	AU 1999-10986	19981014
US 6300485	B1	20011009	US 1998-172422	19981014
PRIORITY APPLN. INFO.:			US 1997-62858P	P 19971015
			US 1997-62241P	P 19971017
			US 1997-68953P	P 19971230
			WO 1998-US21971	W 19981014

AB The amino acid and nucleic acid sequences of a new cyclic nucleotide gated channel-15 (CNGC-15) and Myosin IXa that map to the region of the human chromosome assocd. with Bardet-Biedl Syndrome are disclosed. CNGCs comprise a family of multimeric protein ion channels that open in response to the binding of a cyclic nucleotide to an intracellular domain. The two new proteins, CNGC-15 and Myosin IXa, are useful in the study, diagnosis and treatment of Bardet-Biedl Syndrome and Usher Syndrome. Other indications that can be treated by CNGC-15 and/or Myosin IXa polypeptides, or agonists or antagonists include hearing loss, retinitis pigmentosa, obesity, hypogonadism, sterility, polydactyly, brachydactyly, syndactyly, mental retardation, renal abnormalities, hypertension, diabetes and cardiovascular abnormalities. Compns. and methods for expressing CNGC and Myosin IXa are provided. The compns. comprise CNGC-15 and Myosin IXa and polypeptides and derivs. thereof, nucleotide sequences, expression cassettes, transformed cells and antibodies to these polypeptides. Methods for the expression and detection of CNGC and Myosin IXa nucleotides and polypeptides and compns. for the treatment of these conditions are also provided.

09/627383

IT 222964-43-4, Myosin IXa (human clone BAC)
RL: BSU (Biological study, unclassified); PRP (Properties); THU
(Therapeutic use); BIOL (Biological study); USES (Uses)
(amino acid sequence; amino acid and nucleic acid sequences of
Myosin IXa and cyclic nucleotide gated channel (CNGC) and uses in
diagnosis and treatment of human diseases)

REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE
FOR THIS RECORD. ALL CITATIONS AVAILABLE
IN THE RE FORMAT

L2 ANSWER 21 OF 23 HCAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1999:63638 HCAPLUS

DOCUMENT NUMBER: 130:265212

TITLE: Myr 7 is a novel myosin IX-RhoGAP expressed in
rat brain

AUTHOR(S): Chieregatti, Evelina; Gartner, Annette;
Stoffler, Hanns-Eugen; Bahler, Martin

CORPORATE SOURCE: Friedrich-Miescher Laboratorium in the
Max-Planck Society, Tübingen, 72076, Germany

SOURCE: Journal of Cell Science (1998), 111(24),
3597-3608

CODEN: JNCSAI; ISSN: 0021-9533
PUBLISHER: Company of Biologists Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Rho family GTPases are important regulators of neuronal morphol.,
but the proteins directly controlling their activity in neurons are
still poorly defined. The authors report the identification of myr
7, a novel unconventional myosin IX-RhoGAP expressed in rat brain.
Myr 7 is a multidomain protein related to myr 5, the first class IX
myosin to be characterized. It exhibits a myosin head domain with
an N-terminal extension and a large insertion at loop 2, an actin
contact site and regulator of myosin ATPase rate. The myosin head
domain is followed by a neck domain consisting of six unevenly
spaced consecutive IQ motifs representing light chain binding sites.
The tail domain contains a C6H2-zinc binding motif and a region that
specifically stimulates the GTPase-activity of Rho followed by a
short stretch predicted to adopt a coiled-coil structure. Five
alternatively spliced regions, one in the 5'-noncoding region, two
in the myosin head and two in the tail domain, were noted. Anal. of
myr 7 and myr 5 expression in different tissues revealed that myr 7
is expressed at high levels in developing and adult brain tissue
whereas myr 5 is expressed only at moderate levels in embryonic
brain tissue and at even further reduced levels in adult brain
tissue. Myr 5 is, however, highly expressed in lung, liver, spleen
and testis. Myr 7 is expressed in all brain regions and is
localized in the cytoplasm of cell bodies, dendrites and axons. Myr
5 exhibits an overlapping, but not identical cellular distribution.
Finally, a myr 7 fusion protein encompassing the GAP domain
specifically activates the GTPase-activity of Rho in vitro, and
overexpression of myr 7 in HtTA1-HeLa cells leads to inactivation of
Rho in vivo. These results are compatible with a role for myr 7
(and myr 5) in regulating Rho activity in neurons and hence in
regulating neuronal morphol. and function.

IT 221651-87-2

RL: BOC (Biological occurrence); BPR (Biological process); BSU
(Biological study, unclassified); PRP (Properties); BIOL (Biological
study); OCCU (Occurrence); PROC (Process)

09/627383

(amino acid sequence; cDNA sequence of human and rat myr 7, a novel myosin IX-rhoGAP expressed in rat brain)

REFERENCE COUNT: 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 22 OF 23 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1999:9860 HCAPLUS
DOCUMENT NUMBER: 130:77730
TITLE: sequence of human and mouse neuro-growth factor like protein Zneul and antibodies for detection strategies
INVENTOR(S): Sheppard, Paul O.; Jelinek, Laura J.; Whitmore, Theodore E.; Blumberg, Hal; Lehner, Joyce M.
PATENT ASSIGNEE(S): ZymoGenetics, Inc., USA
SOURCE: PCT Int. Appl., 70 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9857983	A2	19981223	WO 1998-US12763	19980618
WO 9857983	A3	19990318		
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9879798	A1	19990104	AU 1998-79798	19980618
AU 737132	B2	20010809		
EP 996628	A2	20000503	EP 1998-930397	19980618
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002506349	T2	20020226	JP 1999-504836	19980618
PRIORITY APPLN. INFO.:			US 1997-50143P	P 19970618
			US 1997-878322	A 19970618
			WO 1998-US12763	W 19980618

AB A novel mammalian neuro-growth factor like polypeptide Zneul, polynucleotides encoding the polypeptides, and related compns. and detection methods including antibodies and anti-idiotypic antibodies and humanized antibodies and antibody fragments single-chain antibodies are presented. An expression vector is described for effective Zneul protein expression in a eukaryotic cell. In addn., chimeric proteins involving Zneul are described.
IT 218778-65-5 218778-68-8
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(amino acid sequence; sequence of human and mouse neuro-growth factor like protein Zneul and antibodies for detection strategies)

L2 ANSWER 23 OF 23 HCAPLUS COPYRIGHT 2002 ACS

09/627383

ACCESSION NUMBER: 1996:319778 HCAPLUS
DOCUMENT NUMBER: 125:82238
TITLE: Distinct cellular and subcellular patterns of expression imply distinct functions for the Drosophila homologs of moesin and the neurofibromatosis 2 tumor suppressor, merlin
AUTHOR(S): McCartney, Brooke M.; Fehon, Richard G.
CORPORATE SOURCE: Dev., Cell., Molecular Biol. Group., Dep. Zoology, Duke Univ., Durham, NC, 27708-1000, USA
SOURCE: J. Cell Biol. (1996), 133(4), 843-852
CODEN: JCLBA3; ISSN: 0021-9525

DOCUMENT TYPE: Journal
LANGUAGE: English

AB Interest in members of the protein 4.1 super-family, which includes the ezrin-radixin-moesin (ERM) group, has been stimulated recently by the discovery that the human neurofibromatosis 2 (NF2) tumor suppressor gene encodes an ERM-like protein, merlin. Although many proteins in this family are thought to act by linking the actin-based cytoskeleton to transmembrane proteins, the cellular functions of merlin have not been defined. To investigate the cellular and developmental functions of these proteins, Drosophila homologs of moesin (Dmoesin) and the NF2 tumor suppressor merlin (Dmerlin) were identified and characterized. Specific antibodies were used to show that although these proteins are frequently coexpressed in developing tissues, they display distinct subcellular localizations. Whereas Dmoesin is obsd. in continuous assocn. with the plasma membrane, as a typical for an ERM family protein, Dmerlin is found in punctate structures at the membrane and in cytoplasm. Investigation of Dmerlin in cultured cells demonstrates that it is assocd. with endocytic compartments. As a result of these studies, the merlin protein is proposed to have unique functions in the cell which differ from those of other ERM family members.

IT 178535-96-1

RL: BOC (Biological occurrence); PRP (Properties); BIOL (Biological study); OCCU (Occurrence)
(amino acid sequence; distinct cellular and subcellular patterns of expression imply distinct functions for the Drosophila homologs of moesin and the neurofibromatosis 2 tumor suppressor merlin)

SELECT IS APPROXIMATELY 69% COMPLETE
E1 THROUGH E28 ASSIGNED

FILE 'REGISTRY' ENTERED AT 15:41:33 ON 07 JUN 2002
L3 28 SEA FILE=REGISTRY ABB=ON PLU=ON (178535-96-1/BI OR
218778-65-5/BI OR 218778-68-8/BI OR 221651-87-2/BI OR
222964-43-4/BI OR 244613-54-5/BI OR 250313-43-0/BI OR
253582-33-1/BI OR 260386-80-9/BI OR 262988-39-6/BI OR
263525-23-1/BI OR 284706-28-1/BI OR 316927-56-7/BI OR
319502-44-8/BI OR 324745-26-8/BI OR 326928-35-2/BI OR
331287-05-9/BI OR 332001-59-9/BI OR 332001-60-2/BI OR
342874-40-2/BI OR 352374-90-4/BI OR 352374-91-5/BI OR
352374-92-6/BI OR 355157-34-5/BI OR 369659-63-2/BI OR
371995-57-2/BI OR 403520-71-8/BI OR 403546-70-3/BI)

L4 28 L3 AND L1

L4 ANSWER 1 OF 28 REGISTRY COPYRIGHT 2002 ACS

09/627383

RN 403546-70-3 REGISTRY
CN Protein (human clone WO0188088-SEQID-14753 fragment) (9CI) (CA
INDEX NAME)

OTHER NAMES:

CN 2753: PN: WO0188088 SEQID: 14753 claimed protein
CI MAN
SQL 108

SEQ 1 SHAGCLIRFW RKSMTPTHSL PLTPTFLGTC EASFLEPRAS PVPPQCSMAL
=====
51 RRYRLDMGQS FWGGLPSSHP PDPSRPGFVP GVGHVPGQEG PGGKPAPDSS
101 XHXdPTGG

HITS AT: 35-40

REFERENCE 1: 136:227947

L4 ANSWER 2 OF 28 REGISTRY COPYRIGHT 2002 ACS
RN 403520-71-8 REGISTRY
CN Protein (human clone WO0188088-SEQID-12024 fragment) (9CI) (CA
INDEX NAME)

OTHER NAMES:

CN 24: PN: WO0188088 SEQID: 12024 claimed protein
CI MAN
SQL 75

SEQ 1 GHTGPLGSPW SSVWVCLAGR QVPGPQHPHR PPGCSWGCRP PAGTGPRLPS
51 ASAPRCCPPR MRLEPRASRR SGTSG
=====

HITS AT: 63-68

REFERENCE 1: 136:227947

L4 ANSWER 3 OF 28 REGISTRY COPYRIGHT 2002 ACS
RN 371995-57-2 REGISTRY
CN Protein (Propionibacterium acnes strain ATCC6919 clone
WO0181581-SEQID-896 open reading frame) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 896: PN: WO0181581 SEQID: 896 claimed protein
CI MAN
SQL 125

SEQ 1 RISQHVLARR GAHDRRNRC EAGLASSTPPT LTHNEFVAVV GWGHNYRLQN
51 SDRPDRLREF GQFFLVKHFT RLARVRDLDI HGDELEPRAS NTFVYRVAVS
=====

101 TSVINALFVI IIEIRALKQL SETPP
HITS AT: 85-90

REFERENCE 1: 135:353807

L4 ANSWER 4 OF 28 REGISTRY COPYRIGHT 2002 ACS
RN 369659-63-2 REGISTRY
CN Protein (human clone WO0179449-SEQID-7642 fragment) (9CI) (CA INDEX
NAME)

OTHER NAMES:

CN 116: PN: WO0179449 SEQID: 2145 claimed sequence
CI MAN
SQL 119

09/627383

SEQ 1 LTQLKTHCPL IKSKTMNKKR AIREPAQEPG PQKEENPKKH RSPSFTSTS
51 PGLEVPASYS PPTKAEQPGQ VRKAVQPAVR LEPRASHPAG PPVPPSGVLV
=====

101 SRRRPEPGQG KPPESDFDH
HITS AT: 81-86

REFERENCE 1: 135:353783

L4 ANSWER 5 OF 28 REGISTRY COPYRIGHT 2002 ACS

RN 355157-34-5 REGISTRY

CN Protein ECTACC (human) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN GenBank AF220152-derived protein GI 7934572

CI MAN

SQL 906

SEQ 1 MFWYKRRGAP MRPVSVIDGV VCVSPGCGSE TVPVPGPRS DSVEGSPFRP
51 PSHSFSAVFD EDKPIASSGT YNLDFDNIEL VDTFQTLEPR ASDAKNQEGK
===== ==

101 VNTRRKSTD SVPISKSTLSR SLSLQASDFD GASSSGNPEA VALAPDAYST
151 GSSSASSTLK RTKKPRPPSL KKKQTTKKPT ETPPVKETQQ EPDEESLVPS
201 GENLASETKT ESAKTEGPSP ALLEETPLEP AVGPKAACPL DSESAEGVVP
251 PASGGGRVQN SPPVGRKTL P LTTAPEAGEV TPSDSGGQED SPAKGLSVRL
301 EFDYSEDKSS WDNQQENPPP TKKIGKKPVA KMPLRRPKMK KTPEKLDNTP
351 ASPPRSPAEP NDIPIAKGTY TFDIDKWDPP NFNPFSSSTSK MQESPKLPQQ
401 SYNFDPDTCD ESVDPFKTSS KTPSSPSKSP ASFEIPASAM EANGVDGDGL
451 NKPAAKKKTP LKTDTFRVKK SPKRSPPLSDP PSQDPTPAAT PETPPVISAV
501 VHATDEEKLA VTNQKWTMVT VDLEADKQDY PQPSDLSTFV NETKFSSPTE
551 ELDYRNSYEI EYMEKIGSSL PQDDDAPKKQ ALYLMFDTSQ ESPVKSSPVR
601 MSESPTPCSG SSFEETEALV NTAAKNQHPV PRGLAPNQES HLQVPEKSSQ
651 KELEAMGLGT PSEAIIEIREA AHPTDVSISK TALYSRIGTA EVEKPAGLLF
701 QQPDLDSALQ IARAEIITKE REVSEWKDKY EESRREVMEM RKIVAEYEKT
751 IAQMIEDEQR EKSVSHQTVQ QLVLEKEQAL ADLNSVEKSL ADLFRYYEKM
801 KEVLEGFRKN EEVLKRCAQE YLSRVKKEEQ RYQALKVHAE EKLDRANAEI
851 AQVRGKAQQE QAAHQASLRK EQLRVDALER TLEQKNKEIE ELTKICDELI
901 AKMGKS

HITS AT: 87-92

REFERENCE 1: 135:176236

L4 ANSWER 6 OF 28 REGISTRY COPYRIGHT 2002 ACS

RN 352374-92-6 REGISTRY

CN Protein (human clone 784CIF2_39 precursor) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 688: PN: WO0153312 SEQID: 1825 claimed protein

CI MAN

SQL 1025

SEQ 1 MAYASWQRWS PVEWARWMWT AVTSSGDSSL LVLQGDSGKR SSDSEEAFT
51 PESTTPVKAP PAPPPPPEV IPEPEVSTQP PPEEPGCGSE TVPVPGPRS
101 DSVEGSPFRP PSHSFSAVFD EDKPIASSGT YNLDFDNIEL VDTFQTLEPR
=====

151 ASDAKNQEGK VNTRRKSTD SVPISKSTLSR SLSLQASDFD GASSSGNPEA
=====

201 VALAPDAYST GSSSASSTLK RTKKPRPPSL KKKQTTKKPT ETPPVKETQQ
251 EPDEESLVPS GENLASETKT ESAKTEGPSP ALLEETPLEP AVGPKAACPL
301 DSESAEGVVP PASGGGRVQN SPPVGRKTL P LTTAPEAGEV TPSDSGGQED
351 SPAKGLSVRL EFDYSEDKSS WDNQQENPPP TKKIGKKPVA KMPLRRPKMK

09/627383

401 KTPEKLDNTP ASPPRSPAEP NDPIIAKGY TFIDIKWDDP NFNPFSSTSK
451 MQESPKLPQQ SYNFDPDTCD ESVDPFKTSS KTPSSPSKSP ASFEIPASAM
501 EANGVGDGGL NKPAAKKKTP LKTMVEDVMS VCSLFDTFRV KKSPKRSPPLS
551 DPPSQDPTPA ATPETPPVIS AVVHATDEEK LAVTNQKWTM MTVDLEADKQ
601 DYPQPSDLST FVNETKFSSP TEELDYRNSY EIEYMEKIGS SLPQDDDAPK
651 KQALYLMFDT SQESPVKSSP VRMSESPTPC SGSSFEETEA LVNTAAKNQH
701 PVPRGLAPNQ ESHLQVPEKS SQKELEAMGL GTPSEAIEIT APEGSFASAD
751 ALLSRLAHPV SLCGALDYLE PDLAENPPL FAQKLQREAA HPTDVSISKT
801 ALYSRIGTAE VEKPAGLFFQ QPDQLDSALQI ARAEIITKER EVSEWKDKYE
851 ESRREVMEMR KIVAEYEKTI AQMIEDEQRE KSVSHQTVQQ LVLEKEQALA
901 DLNSVEKSLA DLFRRYEKMK EVLEGFRKNE EVLKRCQAQEY LSRVKKEEQR
951 YQALKVHAAEE KLDRANAEIA QVRGKAQEQ AAHQASLRKE QLRVDALERT
1001 LEQKNKEIEE LTKICDELLA KMGKS

HITS AT: 147-152

REFERENCE 1: 135:148240

L4 ANSWER 7 OF 28 REGISTRY COPYRIGHT 2002 ACS
RN 352374-91-5 REGISTRY
CN Protein (human clone 784CIF2_38 precursor) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 687: PN: WO0153312 SEQID: 1824 claimed protein
CI MAN
SQL 966

SEQ 1 MAYASWQRWS PVEWARWMWT AVTSSGDSSL LVLQGDGKRS SSDSEEAFFET
51 PESTTPVKAP PAPPPPPEV IPEPEVSTQP PPEEPGCGSE TVPVPDGPRS
101 DSVEGSPFRP PSHFSAVFD EDKPIASSGT YNLDFDNIEL VDTFQTLEPR
=====
151 ASDAKNQEGK VNTRRKSTDV VPISKSTLSR SLSIQASDFD GASSSGNPEA
==
201 VALAPDAYST GSSSASSTLK RTKKPRPPSL KKKQTTKKPT ETTPVKETQQ
251 EPDEESLVPS GENLASETKT ESAKTEGPSP ALLEETPLEP AVGPKAACPL
301 DSESAEGVVP PASGGGRVQN SPPVGRKTLV LTTAPEAGEV TPSDSGGQED
351 SPAKGLSVRL EFDYSEDKSS WDNQQENPPP TKGKPPVA KMPLRRPKMK
401 KTPEKLDNTP ASPPRSPAEP NDPIIAKGY TFIDIKWDDP NFNPFSSTSK
451 MQESPKLPQQ SYNFDPDTCD ESVDPFKTSS KTPSSPSKSP ASFEIPASAM
501 EANGVGDGGL NKPAAKKKTP LKTDTRVKK SPKRSPLSDP PSQDPTPAAT
551 PETPPVISAV VHATDEEKLA VTNQKWTM VDLEADKQDY PQPSDLSTFV
601 NETKFSSPTE ELDYRNSYEI EYMEKIGSSL PQDDDAPKKQ ALYLMFDTSQ
651 ESPVKSSPVR MSESPPTPCSG SSFEETEALV NTAAKNQHPV PRGLAPNQES
701 HLQVPEKSSQ KELEAMGLT PSEAIEIREA AHPTDVSISK TALYSRIGTA
751 EVEKPAGLFF QQPDLDSALQ IARAEIITKE REVSEWKDKY EESRREVMEMR
801 RKIVAEYEKTI IAQMIEDEQR EKSVSHQTVQ QLVLEKEQAL ADLNSVEKSL
851 ADLFRRYEKMK KEVLEGFRKNE EVLKRCQAQE YLSRVKKEEQR RYQALKVHAA
901 EKLDRANAEI AQVRGKAQEQ QAAHQASLRK EQLRVDALER TLEQKNKEIE
951 ELTKICDELLA AKMGKS

HITS AT: 147-152

REFERENCE 1: 135:148240

L4 ANSWER 8 OF 28 REGISTRY COPYRIGHT 2002 ACS
RN 352374-90-4 REGISTRY
CN Protein (human clone 784CIF2_37 precursor) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 686: PN: WO0153312 SEQID: 1823 claimed protein
CI MAN
SQL 1013

09/627383

SEQ 1 MAYASWQRWS PVEWARWMWT AVTSSGDSSL LVLQGDSGKR SSDSEEAFT
51 PESTTPVKAP PAPPPPPEV IPEPEVSTQP PPEEPGCGSE TVPVPDGPRS
101 DSVEGSPFRP PSHSFSAVFD EDKPIASSGT YNLDFDNIEL VDTFQTLEPR
=====

151 ASDAKNQEKG VNTRRKSTDV VPISKSTLSR SLSLQASDFD GASSSGNPEA
==

201 VALAPDAYST GSSSASSTLK RTKKPRPPSL KKKQTTKKPT ETPPVKETQQ
251 EPDEESLVPS GENLASETKT ESAKTEGPSP ALLEETPLEP AVGPKAACPL
301 DSESAEGVVP PASGGGRVQN SPPVGRKTL P LTTAPEAGEV TPSDSGGQED
351 SPAKGLSVRL EFDYSEDKSS WDNQQENPPP TKKIGKKPVA KMPLRRPKMK
401 KTPEKLDNTP ASPPRSPAEP NDIPIAKGTY TFDIDKWDPP NFNPFSSTSK
451 MQESPPLPQQ SYNFDPDTCD ESVDPFKTS KTPSSPSKSP ASFEIPASAM
501 EANGVGDGGL NKPAAKKKTP LKTDTFRVKK SPKRSPLSDP PSQDPTPAAT
551 PETPPVISAV VHATDEEKLA VTNQKWTCTM VDLEADKQDY PQPSDLSTFV
601 NETKFSSPTE ELDYRNSYEI EYMEKIGSSL PQDDDAPKKQ ALYLMFDTSQ
651 ESPVKSSPVR MSESPPTPCSG SSFEETEALV NTAAKNQHPV PRGLAPNQES
701 HLQVPEKSSQ KELEAMGLGT PSEAIEITAP EGFSFASADAL LSRLAHPVSL
751 CGALDYLEPD LAEKNPPLFA QKLQREAAHP TDVSISKTAL YSRIGTAEVE
801 KPAAGLLFQQP DLDALQIAR AEIITKEREV SEWKDKYEE RREVMEMRKI
851 VAEYEKTIAQ MIEDEQREKS VSHQTVQQLV LEKEQALADI NSVEKSLADL
901 FRRYEKMKEV LEGFRKNEEV LKRCQAQEYLS RVKKEEQRYQ ALKVHAEKLN
951 DRANAEIAQV RGKAQQEQAA HQASLRKEQL RVDALERTLE QKNKEIEELT
1001 KICDELIAKM GKS

HITS AT: 147-152

REFERENCE 1: 135:148240

L4 ANSWER 9 OF 28 REGISTRY COPYRIGHT 2002 ACS
RN 342874-40-2 REGISTRY
CN Calcium channel (Rattus norvegicus brain subunit .alpha.1H) (9CI)
(CA INDEX NAME)

OTHER NAMES:

CN Calcium channel (rat brain subunit .alpha.1H)
CN GenBank AF290213-derived protein GI 11415018
CI MAN
SQL 2359

SEQ 1 MTEGTLAADE VRVPLGASPP APAAPVRASP ASPGAPGREE QGGSGSGVLA
51 PESPGTECGA DLGADEEQPV PYPALAATVF FCLGQTTRPR SWCLRLVCNP
101 WFEHVSMLVI MLNCVTLGMF RPCEDVECRS ERCSILEAFD DFIFAFFFAVE
151 MVIKVALGL FGQKCYLGDT WRNRLDFFIV AGMMEYSLDG HNVSLSAIRT
201 VRVLRPLRAI NRVPSMRILV TLLLDTLPLM GNVLLLCCFFV FFIFGIVGVQ
251 LWAGLLRNRC FLDSAFVRNN NLTFLRPYYQ TEEGEENPFI CSSRRDNGMQ
301 KCSHIPSRRR LRVQCTLGWE AYGQPQAEDG GAGRACINW NQYYNVCRSG
351 EFNPHNGAIN FDNIGYAWIA IFQVITLEGW VDIMYYVMDA HSFYNFIYFI
401 LLIIMGSFFM INLCLVVIAT QFSETKQREN QLMREQRARY LSNDSTLASF
451 SEPGSCYEEL LKYVGHIFRK VKRRSLRLYA RWQSRWRKKV DPSSTVHGQG
501 PGRRPDRAGR RTASVHHLVY HHHHHHHHHY HFSHGGPDRP SPEPGAGDNR
551 LVRACAPPSP PSPGHGPPDS ESVHSIYHAD CHVEGPQERA RVAHSIATAA
601 SLKLASGLGT MNYPTILPSG TVNSKGGS T RPKGLRGAGA PGAAVHSPLS
651 LGSPRPRYEKI QDVVGEOQLG RASSHLSGLS VPCPLPSPQA GTLTCELKSC
701 PYCASALED P EFEFSGSESG DSDAHGVYEF TQDVRHGDCR DPVQQPHEVG
751 TPGHSNERRR TPLRKASQPG GIGHLWASFS GKLRRIVDSK YFNRGIMAAI
801 LVNTLSMGVE YHEQPEELTN ALEISNIVFT SMFALEMLLK LLACGPLGYI
851 RNPYNIFDGI VVVISVWEIV GQADGGQSVL RTFRLRLVVK LVRFLPALRR
901 QLVVLMRTMD NVATFCMLLM LFIFIFSILG MHLFGCKFSL KTDSGDTVPD
951 RKNFDSLWA IVTVFQILTQ EDWNVVLYNG MASTSSWAAL YFVALMTFGN

09/627383

1001 YVLFNLLVAI LVEGFQAEQD ATRSDETD EK TSTQLEGDFD KLRDLRAT EM
1051 KMYSLAVTPN GHLEGRGSLP PPLITHAAT PMPTPKSSPN LDVAHALLDS
1101 RSSSSGSVDP QLGDQKSLAS LRSSPCTPWG PNSAGSSRRS SWNSLGRAPS
1151 LKRRNQCGER ESLLSGEGKG STDDEAEDSR PSTGTHPGAS PGPRATPLRR
1201 AESLDHRSTL DLCPPRPAAL LPTKFHDCNG QMVALPSEFF LRIDSHKEDA
1251 AEFDDIEDS CCFLRLHKVLE PYAPQWCRSR ESWALYLFPQ QNRLRVSCQK
1301 VIAHKMFDHV VLVFIFLNCI TIALERPDID PGSTERAFLS VSNYIFTAIF
1351 VVEMMVKVVA LGLLWGEHAY LQSSWNVLDG LLVLVSLVDI IVAMASAGGA
1401 KILGVLRVVR LLRTLRLPRLV ISRAPGLKLV VETLISSLRP IGNIVLICCA
1451 FFIIFGILGV QLFKGKFYYC EGTDTRNITT KAECHAHYR WVRRKYNFDN
1501 LGQALMSLFV LSSKDGWVNI MYDGLDAVGI DQQPVQNHNP WMLLYFISFL
1551 LIVSFVFLNM FVGVVVNFH KCRQHQEAEE ARRREEKRLR RLERRRKAO
1601 RRPYYADYSH TRRSIHSLCT SHYLDLFITF IICLNVITMS MEHYNQPKSL
1651 DEALKYCNVY FTIVFVFEAA LKLVAFGFR FFKDRWNQLD LAIVLLSIMG
1701 IAЛЕЕIEMNA ALPINPTIIR IMRVLRIARV LKLLKMATGM RALLDTVVQA
1751 LPQVGNLGLL FMLLFFIYAA LGVELFGRL CSEDNPCEGL SRHATFTNFG
1801 MAFLTLFRVS TGDNWNGIMK DTLRECTRED KHCLSYLPAL SPVYFVTFML
1851 VAQFVLVNVV VAVLMKHLEE SNKEAREDAE MDAEIELEMA QGSTAQPPPT
1901 AQESQGTQPD TPNLLVVRKV SVSRMLSLPN DSYMFRPVAP AAAPHSHPLQ
1951 EVEMETYTG P VTSAHSPPLE PRASFQVPSA ASSPARVSDP LCALSPRGTP
== ==
2001 RSLSLSRILC RQEAMHSESL EGKVDDVGGD SIPDYTEPAE NMSTSQASTG
2051 APRSPPCSPR PASVRTRKHT FGQRCISSLR PTLGGDEAEA ADPADEEVSH
2101 ITSSAHPWPA TEPHSPEASP TASPVKGTMG SGRDPRRFCS VDAQSFLDKP
2151 GRPDAQRWSS VELDNGESEL ESGEVGRGRAS ELEPALGSRR KKKMSPPCIS
2201 IEPPTKDEGS SRPPAAEGGN TTLRRRTPSC EAALHRDCPE PTEGPGTGGD
2251 PVAKGERWGQ ASCRAEHTV PNFAFEPLDM GGPGGDCFLD SDQSVTPEPR
2301 VSSLGAIVPL ILETLSMPS PDCPEKEQGL YLTVPQTPLK KPGSTPATPA
2351 PDDSGDEPV

HITS AT: 1969-1974

REFERENCE 1: 135:15597

L4 ANSWER 10 OF 28 REGISTRY COPYRIGHT 2002 ACS
RN 332001-60-2 REGISTRY
CN Bone morphogenetic protein receptors, protein BRK-3 (mouse clone
pJT6-mBRK-3L) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 7: PN: US6210899 SEQID: 8 claimed protein
CI MAN
SQL 2887

SEQ 1 METTHRERS ERLEHISARG PRPHEARGVA LPRTRPLELE TRPALAVALL
51 ELEVALSERT HRTHRHALAAL ASERGLNASN GLNGLARGLE CYSALAPHEL
101 YSASPPRTYR GLNGLNASPL EGLYILEGLY GLSERARGIL ESERHISGLA
151 SNGLYTHRIL ELEYCSSLRL YSGLYSERTH RCYSTYRGLY LETRPGLLYS
201 SERLYSGLYA SPILEASNLE VALLYSGLNG LYCYSTRPSE RHISILEGLY
251 ASPPRGLNGL CYSHISTYRG LGLCYSVALV ALTHRTHRTH RPRPRSERIL
301 EGLNASNGLY THRTYRARGP HECYSCYSCY SSERTHRASP LECYSASNVA
351 LASNPHETHR GLASNPHPR PRPRASPTHR THRPRLESER PRPRHISSE
401 PHEASNARGA SPGLTHRILE ILEILEALAL EALASERVAL SERVALLEAL
451 AVALLEILEV ALALALECYS PHEGLTYRA RGMETLETHR GLYASPARGL
501 YSGLNGLYLE HISSERMETA SNMETMETGL ALAALAALAA LAGLPRSERL
551 EASPLEASPA SNLELYSLEL EGLLEILEGL YARGGLYARG TYRGLYALAV
601 ALTYRLYSGL YSERLEASPG LARGPRVALA LAVALLYSVA LPHESERPHE
651 ALAASNARGG LNASNPHIEL EASNGLLYSA SNILETYRAR GVALPRLEME
701 TGLHISASPA SNILEALAAR GPHEILEVAL GLYASPGLAR GLETHRALAA
751 SPGLYARGME TGLTYRLELE VALMETGLTY RTYRPRASNG LYSERLECYs

09/627383

801 LYSTYRLESE RLEHISTHRS ERASPTRPVA LSERSERCYS ARGLEALAH
851 SSERVALTHR ARGGLYLEAL ATYRLEHIST HRGLLEPRAR GGLYASPHIS
901 TYRLYSPRAL AILESERHIS ARGASPLEAS NSERARGASN VALLEVALY
951 SASNASPGLY ALACYSVALI LESERASPPH EGLYLESERM ETARGLETHR
1001 GLYASNARGL EVALARGPRG LYGLGLASPA SNALAALAIL ESERGLVALG
1051 LYTHRILEAR GTYRMETALA PRGLVALLEG LGYALALAV ASNLEAR GAS
1101 PCYSGLSERA LALELYSGLN VALASPMETT YRALALEGLY LEILETYRTR
1151 PGLVALPHEM ETARGCYSTH RASPLEPHEP RGLYGLSERV ALPRASPTYR
1201 GLNMETALAP HEGLNTHRGL VALGLYASNH ISPRTHRPH GLASPMETGL
1251 NVALLEVALS ERARGGLLYS GLNARGPRLY SPHEPRLAL ATRPLYSGLA
1301 NSERLEALA VALARGSERL ELYSGLTHRI LEGLASPCYS TRPASPGNA
1351 SPALAGLALA ARGLETHRAL AGLNCYSALA GLGLARGMET ALAGLLEMET
1401 METILETRPG LARGASNLYS SERVALSERP RTHRVALASN PRMETSERTH
1451 RALAMETGLN ASNGLARGAS NLESERHISA SNARGARGVA LPRLYSILEG
1501 LYPRTYRPRPRA SPTYRSERSE RSERSERTYR ILEGLASPSE RILEHISHIS
1551 THRASPSEI LEVALLYSAS NILESERSER GLHISSEME TSERSERTHR
1601 PRLETHRILE GLYGLLYSAS NARGASNSER ILEASNTYRG LARGGLNGLN
1651 ALAGLNALAA RGILEPRSER PRGLTHRSE RVALTHRSE RERTHRASN
1701 THRTHRTHRT HRASNTHRTH RGLYLETHRP RSERTHRGLY METTHRTHRI
1751 LESERGLMET PRTYPRASP GLTHRHI SLEALATHRA SVALALAGL
1801 NSERILEGLY PRTHRPRVAL CYSLEGLNLE THRGGLASP LEGLTHRASN
1851 LYSLEASPPR LYSGLVALAS PLYSASNLE YSGLSERSER ASPGLASNL
1901 METGLHISSE RLELYSGLNP HESERGLYPR APPRLESER SERTHRERS
1951 ERSERLELET YRPRLEILEL YSLEALALAV GLVALTHRGL YGLNGLNASP
2001 PHETHRGLNA LAALAASNGL YGLNALACYS LEILEPRASP VALPRPRA
=====

2051 GLNILETYRP RLEPRLYSGL NGLNASNLEP RLYSARGPRT HRSERLEPRL
2101 EASNTHRLYS ASNTERHRL YSGLPRARGL ELYSPHEGLY ASNLYSHISL
2151 YSSERASNLE LYSGLNVALG LTHRGGLYVAL ALALYSMETA SNTHRILEAS
2201 NALAALAGLP RHISVALVAL THRVALTHR ETASNGLYVA LALAGLYARG
2251 SERHISASNV ALASNTERHI SALAALATHR THRGGLNTYRA LAASNGLYAL
2301 AVALPRAAG LYGLNALAAL AASNILEVAL ALAHISARGS ERGLNGLMET
2351 LEGLNASNGL NPHEILEGLY GLASPTHRAR GLEASNILEA SNSERSERPR
2401 ASPGLHISGL PRLEEARGA RGGLGLNGLN ALAGLYHISA SPGLGLYVAL
2451 LEASPARGLE VALASPARGA RGGLARGPRL EGLGLYGLY RGTHRASN
2501 RASNASNASN ASNTERASNP RCYSSERGLG LNAPILELE THRGGLNGLYV
2551 ALTHRSETH RALAALAASP PRGLYPRSER LYSPRARGAR GALAGLNARG
2601 PRASNTERLE ASPLESERAL ATRASNILE LEASPGLYSE RSERILEGLN
2651 ILEGLYGLSE RTHRGGLNASP GLYLYSSERG LYSERGLYGL LYSILELYSA
2701 RGARGVALY STHRPRTYRS ERLELYSARG TRPARGPRSE RTHRTRPVAL
2751 ILESERTHRG LPRLEASPCY SGLVALASNA SNASNGLYSE RASPARGALA
2801 VALHISSERL YSSERSETH RALAVALTYR LEALAGLGLY GLYTHRALAT
2851 HRTHRTHRVA LSERLYSASP ILEGLYMETA SNCYSLE

HITS AT: 2034-2039

REFERENCE 1: 134:261275

L4 ANSWER 11 OF 28 REGISTRY COPYRIGHT 2002 ACS
RN 332001-59-9 REGISTRY
CN Bone morphogenetic protein receptors, protein BRK-3 (human foreskin
fibroblast clone pHSK1040) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 2: PN: US6210899 SEQID: 2 claimed protein
CI MAN
SQL 2887

SEQ 1 METTHRSE RERLEGLNARG PRTRPARGVA LPRTRPLEPR TRPTHRILEL
51 ELEVALSERT HRALALAAL ASERGLNASN GLNGLARGLE CYSALAPHEL

101 YSASPPRTYR GLNGLNASPL EGLYILEGLY GLSERARGIL ESERHISGLA
 151 SNGLYTHRIL ELEYCSSLR YSGLYSERTH RCYSTYRGLY LETRPGLLYS
 201 SERLYSGLYA SPILEASNLE VALLYSGLNG LYCYSTRPSE RHISILEGLY
 251 ASPPRGLNGL CYSHISTYRG LGLCYSVALV ALTHRTHRTH RPRPRSERIL
 301 EGLNASNGLY THRTYRARGP HECYSCYSCY SSERTHRASP LECYSASNVA
 351 LASNPHETHR GLASNPHESP RPRASPRTHR THRPRLESER PRPRHISSE
 401 PHEASNARGA SPGLTHRILE ILEILEALAL EALASERVAL SERVALLEAL
 451 AVALLEILEV ALALALECYS PHEGLTYRA RGMETLETHR GLYASPARGL
 501 YSGLNGLYLE HISSERMETA SNMETMETGL ALAALAALAS ERGLPRSERL
 551 EASPLEASPA SNLELYSLEL EGLLEILEGL YARGGLYARG TYRGLYALAV
 601 ALTYRLYSGL YSERLEASPG LARGPRVALA LAVALLYSVA LPHESERPHE
 651 ALAASNARGG LNASNPHESL EASNGLLYSA SNILETYRAR GVALPRLEME
 701 TGLHISASPA SNILEALAAR GPHEILEVAL GLYASPGALAR GVALTHRHALA
 751 ASPGLYARGM ETGLTYRLEL EVALMETGLT YRTYRPRASN GLYSERLECY
 801 SLYSTYRLES ERLEHISTHR SERASPTRPV ALSERSERCY SARGLEALAH
 851 ISSERVALTH RARGGLYLEA LATYRLEHIS THRGGLPRA RGGLYASPHI
 901 STYRLYSPRA LAILESERHI SARGASPLEA SNSEARGAS NVALLEVALL
 951 YSASNAPGL YTHRCYSVAL ILESERASPP HEGLYLESER METARGLETH
 1001 RGLYASNARG LEVALARGPR GLYGLGLASP ASNALAALAI LESERGLVAL
 1051 GLYTHRILEA RGTYRMETAL APRGLVALLE GLGLYALAVA LASNLEARGA
 1101 SPCYSGLSER ALALELYSGL NVALASPMET TYRALALEGL YLEILETYRT
 1151 RPGLILEPHE METARGCYST HRASPLEPHE PRGLYGLSER VALPRLTYR
 1201 GLNMETALAP HEGLNTHRGL VALGLYASNH ISPRTHRPH GLASPMETGL
 1251 NVALLEVALS ERARGGLLYS GLNARGPRLY SPHEPGLAL ATRPLYSGLA
 1301 SNSEARLEALA VALARGSERL ELYSGLTHRI LEGLASCPCYS TRPASPGNLA
 1351 SPALAGLALA ARGLETHRAL AGLNCYSALA GLGLARGMET ALAGLLEMET
 1401 METILETRPG LARGASNLYS SERVALSERP RTHRVALASN PRMETSERTH
 1451 RALAMETGLN ASNGLARGAS NLESERHISA SNARGARGVA LPRLYSILEG
 1501 LYPRTYRPRAS PPTYRSERSE RSERSERTYR ILEGLASPSE RILEHISHIS
 1551 THRASPSEI LEVALLYSAS NILESERSER GLHISSEME TSERSERTHR
 1601 PRLETHRILE GLYGLLYSAS NARGASNSER ILEASNTYRG LARGGLNGLN
 1651 ALAGLNALAA RGILEPRSER PRGLTHRSE VATHRSE RL SERTHRASN
 1701 THRTHRTHRHT HRASNTHRTH RGLYLETHRP RSERTHRGLY METTHRTHRI
 1751 LESERGLMET PRTYRPRASP GLTHRASNLE HISTHRTHRA SNVALALAGL
 1801 NSERILEGLY PRTHRPRVAL CYSLEGLNLE THRGGLGLASP LEGLTHRASN
 1851 LYSLEASPPR LYSGLVALAS PLYSASNLEL YSGLSERSER ASPGLASNL
 1901 METGLHISSE RLELYSGLNP HESERGLYPR APPRLESER SERTHRERS
 1951 ERSERLELET YRPRLEILEL YSLEALAVL GLALATHRGL YGLNGLNAP
 2001 PHETHRGLNT HRALAASNGL YGLNALACYS LEILEPRASP VALLEPRTHR
 ======
 2051 GLNILETYRP RLEPLYSGL NGLNASNLEP RLYSARGPRT HRSERLEPRL
 2101 EASNTHRLYS ASNSEERTHRL YSGLPRARGL ELYSPHEGLY SERLYSHISL
 2151 YSSERASNL YSGLNVALG LTHRGGLYVAL ALALYSMETA SNTHRILEAS
 2201 NALAALAGLP RHISVALVAL THRVALTHRM ETASNGLYVA LALAGLYARG
 2251 ASNHISSEV ALASNSEERTHRL SALAALATHR THRGGLNTYRA LAASNGLYTH
 2301 RVALLESERG LYGLNTHRTH RASNILEVAL THRHSARGA LAGLNGLMET
 2351 LEGLNASNGL NPHEILEGLY GLASPTHRAR GLEASNILEA SNSEASERPR
 2401 ASPGLHISGL PRLELEARGA RGGLGLNGLN ALAGLYHISA SPGLGLYVAL
 2451 LEASPARGLE VALASPARGA RGGLARGPRL EGLGLYGLY RGTHRASNSE
 2501 RASNASNASN ASNSEASNP RCYSSERGLG LNASPVALLE ALAGLNGLYV
 2551 ALPRSERTHR ALAALAASPP RGLYPRSERL YSPRARGARG ALAGLNARGP
 2601 RASNSEERLEA SPLESERALA THRASNVAL EASPGLYSER SERILEGLNI
 2651 LEGLYGLSER THRGGLNAPG LYLYSSERGL YSERGLYGLL YSILELYSLY
 2701 SARGVALLYS THRPRTYRSE RLELYSARGT RPARGPRSER THRTRPVALI
 2751 LESERTHRGL SERLEASPCY SGLVALASNA SNASNGLYSE RASNARGALA
 2801 VALHISSEV YSSERSEERTH RALAVALTYR LEALAGLGLY GLYTHRALAT
 2851 HRTHRHMETVA LSERLYASAP ILEGLYMETA SNCSYSL

HITS AT: 2034-2039

09/627383

REFERENCE 1: 134:261275

L4 ANSWER 12 OF 28 REGISTRY COPYRIGHT 2002 ACS
RN 331287-05-9 REGISTRY
CN 1: PN: WO0119971 SEQID: 1 unclaimed protein (9CI) (CA INDEX NAME)
CI MAN
SQL 682

SEQ 1 METSERLYSL ESERVALPHE PHEILEPHEL EPHECYSSER ILEALATHRA
51 LAALAGLSE LEPRASPLEL YSILEGLLLYS LEASPGLGLY VALTYRVALH
=====

101 ISTRHRSERPH EGLGLVALAS NGLYTRPGLY VALVALPRLY SHISGLYLEV
151 ALVALLEVAL ASNALAGLAL ATYRLEILEA SPTHRPRPHE THRALALYSA
201 SPTHRGLLYS LEVALTHRTR PPHEVALGLA RGGLYTYRLY SILELYSGLY
251 SERILESERS ERHISPHEHI SSERASPSPER THRGLYGLYI LEGLTRPLEA
301 SNSEARGSE RILEPRTHTR YRALASERGL LETHRASNGL LELELYSGLY
351 ASPGLYLYSV ALGLNALATH RASNSEPRHE SERGLYVALA SNTYRTRPLE
401 VALLYSASNL YSILEGLVAL PHETYRPRGL YPRGLYHIST HRPRASPASN
451 VALVALVALT RPLEPRLAR GLYSILELEP HEGLYGLCY SPHEILELYS
501 PRTYRGLYLE GLYASNLEGL YASPALAASN ILEGLALATR PPRLYSSERA
551 LALYSLELEL YSSERLYSTY RGLYLYSALA LYSLEVALVA LPRSERHIS
601 ERGLVALGLY ASPALASERL ELELYSLETH RLEGLGLNAL AVALLYSGLY
651 LEASNGLSER LYSLYSPRSE RLYSPRSERA SN

HITS AT: 61-66

REFERENCE 1: 134:248841

L4 ANSWER 13 OF 28 REGISTRY COPYRIGHT 2002 ACS
RN 326928-35-2 REGISTRY
CN Protein (human clone PLACE1004777) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 168: PN: EP1074617 SEQID: 12736 claimed protein
CI MAN
SQL 526

SEQ 1 MDRASVCKLC KYACHKKCCL KTTAKCSKKY DPELSSRQFG VELSRLTSED
51 RTVPLVVEKL INYIEMHGLY TEGIYRKSGS TNKIKELRQG LTDADAEVNL
101 DDYNIHVIAS VFKQWLRDLP NPLMTFELYE EFLRAMGLQE RKE TIRGVYS
151 VIDQLSRTHL NTLERLIFHL VRIALQEDTN RMSANALAAIV FAPCILRCPD
201 TTDPLQSVQD ISKTTTCVEL IVVEQMNKYK ARLKDISSLE FAENKAKTRL
251 SLIRRSMGKG RIRRGNYPGP SSPVVVRILPS VSDVSEETLT SEAAMETDIT
301 EQQQQAAMQQE ERVLTEQIEN LQKEKEELTF EMLVLEPRAS DDETLESEAS
=====

351 IGTADSSEN L NMESEYAI SE KSERSLALSS LKTAGKSEPS SKLRKQLKKQ
401 QDSLDVVDSS VSSLCLSNTA SSHGTRKLFQ IYSKSPFYRA ASGNEALGME
451 GPLGQTKFLE DKPQFISRGF FNPEKGKQKL KNVKNSPQKT KETPEGTVMS
501 GRRKTVDPDC TSNQQLALFG NNEFMV

HITS AT: 335-340

REFERENCE 1: 134:188985

L4 ANSWER 14 OF 28 REGISTRY COPYRIGHT 2002 ACS
RN 324745-26-8 REGISTRY
CN L-Serine, L-leucyl-L-.alpha.-glutamyl-L-prolyl-L-arginyl-L-alanyl-
(9CI) (CA INDEX NAME)
SQL 6

09/627383

SEQ 1 LEPRAS

=====

HITS AT: 1-6

REFERENCE 1: 134:159864

L4 ANSWER 15 OF 28 REGISTRY COPYRIGHT 2002 ACS
RN 319502-44-8 REGISTRY
CN 8: PN: WO0102561 SEQID: 26 unclaimed protein (9CI) (CA INDEX NAME)
CI MAN
SQL 2359

SEQ 1 MTEGTLAADE VRVPLGASPP APAAPVRASP ASPGAPGREE QGGSGSGVLA
51 PESPGTECGA DLGADEEQPV PYPALAATVF FCLGQTTRPR SWCLRLVCNP
101 WFEHVSMVLI MLNCVTLGMF RPCEDVECRS ERCSILEAFD DFIFAFFAVE
151 MVIKMWALGL FGQKCYLGDT WRNRLDFFIVM AGMMEYSLDG HKVSLSAIRT
201 VRVLRPLRAI NRVPSMRILV TLLLDLPLML GNVLLLCFFV FFIFGIVGVQ
251 LWAGLLRNRC FLDSAFAVRNN NLTFLRPYYQ TEEGEENPFI CSSRRDNGMQ
301 KCSHIPSRE LRVQCTLGWE AYGQPQAEDG GAGRNACINW NQYYNVCRSG
351 EFNPHNGAIN FDNIGYAWIA IFQVITLEGW VDIMYYVMDA HSFYNFIYFI
401 LLIIMGSFFM INLCLVVIAT QFSETKQREN QLMREQRARY LSNDSTLASF
451 SEPGSCYEEL LKYVGHIFRK VKRRSLRLYA RWQSRWRKKV DPSSTVHGQG
501 PGRRPRAAGR RTASVHHLVY HHHHHHHHHY HFSHGGPGRP SPEPGAGDNR
551 LVRACAPPSP PSPGHGPPDS ESVHSIYHAD CHVEGPQERA RVAHSIATAA
601 SLKLASGLGT MNYPTILPSG TVNSKGGTSS RPKGLRGAGA PGAAVHSPLS
651 LGSPRPLYEKI QDVVGEOQLG RASSHLSGLS VPCPLPSPQA GTLTCELKSC
701 PYCASALEDP EFEFSGSESG DSDAHGVYEF TQDVRHGDCR DPVQQPHEVG
751 TPGHSNERRR TPLRKASQPG GIGHLWASFS GKLRRIIVDSK YFNRGIMAAI
801 LVNTLSMGVE YHEQPEELTN ALEISNIVFT SMFALEMLLK LLACGPLGYI
851 RNPYNIFDGI VVVISVWEIV GQADGGQSVL RTFRLLRVLK LVRFLPALRR
901 QLVVLMRTMD NVATFCMLLM LFIFIFSIIG MHLFGCKFSL KTDGDTVPD
951 RKNFDSLLWA IFTVFQILTO EDWNVVLYNG MASTSSWAAL YFVALMTFGN
1001 YVLFNLLVAI LVEGFQAEQD ATRSDTDEDK TSTQLEGDFD KLRDLRATEM
1051 KMYSLAVTPN GHLEGRGSLP PPLITHATAAT PMPTPKSSPN LDVAHALLDS
1101 RSSSSGSVDP QLGDQKSLAS LRSSPCTPWG PNSAGSSRRS SWNSLGRAPS
1151 LKRRSQCGER ESLLSGEGKG STDDEAEDSR PSTGTHPGAS PGPRATPLRR
1201 AESLDHRSTL DLCPPRPAPP AVQVHDCNGQ MVALPSEFFL RIDSHKEDAA
1251 EFDDDEDSC CFRLHKVLEP YAPQWCRSRE SWALYLFPQQ NRLRVSCQKV
1301 IAHKMFHDVV LVFIFLNCIT IALERPDIDP GSTERAFLSV SNYIFTAIFV
1351 VEMMVKVVAL GLLWGEHAYL QSSWNVLDGL LVLVSLVDII VAMASAGGAK
1401 ILGVLRVVRL LRTLRLRVI SRAPGLKLVV ETLISSLRPI GNIVLICCAF
1451 FIIIFGILGVQ LFKGKFYYCE GTDTRNITTK AECHAAYRW VRRKYNFDNL
1501 GQALMSLFLV SSKDGWVNIM YDGLDAVGID QQPVQNHNPW MLLYFISFLL
1551 IVSFFVLMNF VGVVVENFHK CRQHQEAEEA RRREEKRLRR LERRRKQAQR
1601 RPYYADYSHT RRSIHSLCTS HYLDLIFTI ICLNVITMSM EHYNQPKSLD
1651 EALKYCNYVF TIVFVFEAL KLVAFGFRRF FKDRWNQLDL AIVLLSIMGI
1701 ALEEEIEMNAA LPINPTIIRI MRVLRIARVL KLLKMATGMR ALLDTVVQAL
1751 PQVGNLGLLF MLLFFIYAAI GVELFGRLEC SEDNPCEGLS RHATFTNFGM
1801 AFLTLFRVST GDNWNGIMKD TLRECTREDK HCLSYLPALS PVYFVTFMLV
1851 AQFVLVNVVV AVLMKHLEES NKEAREDAEM DAEIELEMAQ GSTAQPPPTA
1901 QESQGTQPDT PNLLVVRKVS VSRMLSLPND SYMFRPVAPA AAPHSHPQ
1951 VEMETYTGTV TSAHSPPLEP RASFQVPSAA SSPARVSDPL CALSPRGTPR
=====

2001 SLSLSRILCR QEAMHSESLE GKVVDDVGGDS IPDYTEPAEN MSTSQASTGA
2051 PRSPPCSPRP ASVRTRKHTF GQRCISSLRPP TLGGDEAEAA DPADEEVSHI
2101 TSSAHPWPAT EPHSPEASPT ASPVKGTMGS GRDPRRFCGV DAQSFLDKPG
2151 RPDAQRWSSV ELDNGESHLE SGEVRGRASE LEPALGSRRK KKMSPPCISI
2201 EPPTKDEGSS RPPAAEGGNT TLRRRTPSCE AALHRDCPEP TEGPGTGGDP

09/627383

2251 VAKGERWGQA SCRAEHLTVP NFAFEPLDMG GPGGDCFLDS DQSVTPEPRV
2301 SSLGAIIVPLI LETELSMPPSP DCPEKEQGLY LTVQQTPLKK PGSTPATPAP
2351 DDSGDEPVZ
HITS AT: 1968-1973

REFERENCE 1: 134:111253

L4 ANSWER 16 OF 28 REGISTRY COPYRIGHT 2002 ACS
RN 316927-56-7 REGISTRY
CN 10: PN: WO0100822 SEQID: 10 unclaimed protein (9CI) (CA INDEX NAME)
CI MAN
SQL 3096

SEQ 1 METGLGLPHE ASPLEVALY STHRLEHISL YSTHRSESE RSERVALGLY
51 SERASPGLAS NSERLEHISS ERLEGLYLEA SNLEASNTHR ASPARGSERS
101 ERPRHISLES ERTHRASNGL YVALSERSER PHESERGLYL YSTHRARGPR
151 SERVALILEG LNGLYTHRVA LGLVALLETH RSERLEMETG LNGLLEGLNA
201 SNSERGLYL STHRASPSE GLLETRPLYS ASNCGSGLTH RARGTRPLEG
251 LNLEPHEASN LEVALGLLYS GLNCYSGLNG LGNLNILEVAL ALAGLNGLNG
301 LGLNPHHEHIS ASNGLNILEG LNHISILEGL NGLGLILELY SASNLEVALL
351 YSLEGLNTHR SERSERALAS ERLEALASER CYSGLGLYAS NSERSERASN
401 LYSGLNVALS ERSERGLSER GLNMETGLYP HEPHESERLE SERSERGLAR
451 GASNGLSERV ALILEHISTY RPRGLSERTH RGLPRLGLILE GLNGLNGLME
501 TSERTHRSER GLNPRASPCY SASNVALASP SERCYSSERV ALSERSERGL
551 YTYRGLYTHR PHECYSILES ERGLLEASNL ETYRLYSSER LYSASPPRLY
601 SGLPHEMETG LHISILEASP VALPRLYSG YGLNTYRVAL ALAPRALAVA
651 LPRALAGLSE RLEVALASPG LYVALLYSAS NGLASNPHET YRILEGLNTH
701 RPRGLGLCYS HISVALSERL ELYSGLASPV ALSERILESE RPRGLYGLPH
751 EGLHISASNP HELEGLYGLA SNLYSVALSE RGLVALTYRS ERGLYLYSTH
801 RASN SERERASN ALAILETHRS ERTRPALAGL NLYSLELYSG LNASNGLNPR
851 LYSARGALAH ISVALGLASP GLYGLYSERA RGSERLYSGL NGLYASNGLG
901 LNSERLYS STHRPRILEG LLYSSEERASP PHEALAALAA LATHRHSI
951 ARGALAPHET YRLESERLYS PRASPGLTHR PRASNALATR PMETSERASP
1001 SERGLYTHR LYLETHR TYR TRPLYSLEGL GLLYSASPME THISISSE
1051 LEPRGLTHR EGGLYSTHRP HEILESERLE SERSERTHRA SPVALSERPR
1101 ASNGLNVAL ETHRLEASPP RTHRLEHISM ETLYSPLYS GLNGLNILES
1151 ERGLYILEGL NPRHISGLYL EPRASNALAL EASPASPARG ILESERPHES
= =====
1201 ERPRASPSER VALLEGLPRS ERMETSERSE RPRSERASPI LEASPSEPH
1251 ESERGLNALA SERASNVALT HRSERGLNLE PRGLYPHEPR LYSTYRPRSE
1301 RHISTHRLYS ALASERPRVA LASPERTRP LYSASNGLNT HRPHEGLNAs
1351 NGLSERARGT HRSERERTH RPHEPRSERV ALTYRTHRIL ETHRSEASN
1401 ASPILESERV ALASNTHRVA LASPGLGLAS NTHRVALMET VALALASERA
1451 LASERVALSE RGLNSERGLN LEPRGLYTHR ALAASNNSERV ALPRGLCYSI
1501 LESERLETHR SERLEGLASP PRVALILELE SERLYSILEA RGGLNASNLE
1551 LYSGLLYSHI SALAARGHIS ILEALAASPL EARGALATYR TYRGLSERGL
1601 ILEASN SERL ELYSGLNLYS LEGLALALYS GLILESERGL YVALGLASPT
1651 RPLYSILETH RASNGLNILE LEVALASPAR GCYSGLYGLN LEASPSERAL
1701 ALEHISGL ALTHRSEARG VALARGTHR EGLASNLYSA SNASNLELEG
1751 LILEGLVALA SNASPLEARG GLARGPHSE RALAALASER SERALASERL
1801 YSILELEG LNGLAILEGL GLMETARGTH RSERERLYS GLLYSASPAS
1851 NTHRILEILE ARGLELYSSE RARGLEGINA SPLEGLGLAL APHEGLASNA
1901 LATYRLYSLE SERASPASPL YSGLALAGLN LELYSGLNL ASNLYSMEETP
1951 HEGLNASPLE LEGLYGLTYR GLSERLEGLY LYSGLHISAR GARGVALLYS
2001 ASPALALEAS NTHRTHRGLA SNLYSLEEA SPALATYRTH RGLNILESER
2051 ASPLELYSAR GMETILESER LYSLEGLALA GLNVALLYSG LNALGLHIS
2101 GLASNMETLE SERLEARHIS SASN SERARG ILEHISVALA RGPRSERARG
2151 ALAASNTHRL EALATHRSER ASPVALSERA RGARGLYSTR PLEILEPRGL

09/627383

2201 YALAGLTYRS ERILEPHETH RGLYGLNPR L EASPTHRGLN ASPSERASNV
2251 ALASPASNGL NLEGLGLTHR CYSSERLEGL YHISARGSER PRLEGGLYSA
2301 SPSERSERPR GLYSERSERS ERTSRERLE LEILELYSLY SGLNARGGLT
2351 HRSERASPTH RPRILEMETA RGALALELYS GLLEASPGLG LYLYSILEPH
2401 ELYSASNTRP GLYTHRGLNT HRGLLYSGLA SPTHRSERAS NILEASNPR
2451 RGGLNTHRGL THRSEVALA SNALASERAR GSERPRGLLY SCYSALAGLN
2501 GLNARGGLNL YSARGLEASN SERALASERG LNARGSERSE RSERLEPRPR
2551 SERASNARGL YSSERSERTH RPRTHRLYSA RGGLILEMET LETHRPRVAL
2601 THRVALALAT YRSERPRLYS ARGSERPRLY SGASNLESE RPRGLYPHES
2651 ERHISLELES ERLYSASNGL SERSERPRIL EARPHEASP ILELELEASP
2701 ASPLEASPTH RVALPRVALS ERTHRLEGLN ARGTHRASNP RARGLYSGLN
2751 LEGLNPEHE PRLEASPASP SERGLGLYS THRTYRSERG LLYSALATHR
2801 ASPASN HISV ALASN HISSE RSERCYSPRG LPRVALPRAS NGLYVALLY
2851 LYSVALSERV ALARGTHRAL ATRPGGLYSA SNLYSSERVA LSERTYRGLG
2901 LNCYSLYSPR VALSERVALT HRPRGLNGLY ASNASPPHEG LTYRTHRALA
2951 LYSILEARGT HRLEALAGLT HRGLARGPHE PHEASPGLE THR LYSGLLY
3001 SASPGLNILE GLALAALALE SERARGMETP RSERPRGLYD LYARGILETH
3051 RLEGLNTHRA RGLEASNGLN VALLYSCYSL ESERLEASNL ELEEND

HITS AT: 1170-1175

REFERENCE 1: 134:82484

L4 ANSWER 17 OF 28 REGISTRY COPYRIGHT 2002 ACS
RN 284706-28-1 REGISTRY
CN Protein (Xylella fastidiosa gene XF1737) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN GenBank AE003997-derived protein GI 9106807
CI MAN
SQL 242

SEQ 1 MKPSRRSVLK SMGLLAAMPW LLPASRAFAA APMRIGVIGA GSLGGTVGRL
51 WVKAGHEVMF SSRNPDKLEA MARELEPRAS VGQPLAATEF GTVLLAVPF
=====
101 EALPQVGRDL RSAYRGKIVL DSTNPWGASS ADVYREAREL GVAQTVVKYM
151 PGARLVRAFS AVDATVVETS ASRRGGGRIGM PLASDDAEAM KVAEGLVRDA
201 GCDPVIVGML AAAASFQPGG PGFRAHTAP ELRRRLGLPA AS

HITS AT: 75-80

REFERENCE 1: 133:130477

L4 ANSWER 18 OF 28 REGISTRY COPYRIGHT 2002 ACS
RN 263525-23-1 REGISTRY
CN Protein (Drosophila melanogaster gene CG12263) (9CI) (CA INDEX
NAME)
OTHER NAMES:
CN GenBank AE003799-derived protein GI 7302608
CI MAN
SQL 1077

SEQ 1 MNLTYLFVLI WLAFLISSGV MLFSRGFLA RVSKTETSTC RRLSTNPNAE
51 YVLTDEVVNE IFKDVNASSN LCLPQKSKVI VLVVDALKYE FGLYRANATD
101 PLPYENKLVV LQELLQQNPD HARLMRFRAD PPTTTLQRLK GLTTGSLPTF
151 IDIGSNFASP EINEDNIIDQ IVKNDLPPVF LGDSTWTDLY PHRFKRSYSY
201 PSFDIFDLDs VDNEILKHLP KELESKDQWV LVAHFLGVDH CGHKHGPMHE
251 EMARKLGEMN EVIRSVVAAM DNDTLLVMG DHGMTASGDH GGDTDDETNA
301 LLFAYSKQHR FYGNDSGSDS EMLQQIDLVP TLATILGVPI PYSNLGLVNF
351 NIVPDLRVPH LNKFQTLLLH SWQNAQQIYR YFFQYALENK RTFNVEQMDH
401 LETEFILLTH RVQTVYNEVA FKSFVRDLNT NLRDILGTCR EIWVRFDPQ

09/627383

451 MSQGLLFTFL PLFFIFLVVN NSRPADFPHI FKAKEVFYVY LINLAAGVFG
501 YRYFKTFSFK TEEQGVIFFT AISSAVILAF HTLRHWTSA TNWSAVKRGF
551 HMPTRLLLFG SMAVFFSNSF VIQEAKILSY LLAAAILLS HELLRLSARL
601 DFRTKFKASQ FLRSTALRLI LASVLAICLI RFAYTLFRCR EEQGNCSDFV
651 NTGGAGFSLK KPGTGKTYIL AVVVLVYVTT LTRLYLRSCG NLTGNLPNVL
701 LARYGPTVAS ICAGGHILLA NSSIKHIQRT HIDAMALVIY GLLLVQIIVL
751 SWAPLMTFVL PPRSSHTVTI NGNESIVPEI FRKMKRMYEG DDDERRSHIP
801 VVYGLATVYS SIVIAFGVFL ALVMIVLLEP RASIGLVVCV AVGAILLSVH
=====

851 SILRYRTATS FESCVQPTFT ALVGWFLLAH FCFFATSHQT TLSQIEWRAA
901 FVGRTTGIGQ SNLVSGALVI LNTFCGPIFF FCMYSSLSTE TFSLFALFPN
951 LIRSCRSGGK VDASTSMSDL ANEAVGFDMDT RGELSLYEE DVFLGTGFKL
1001 ATQFFMLQGL KIFCAMLACT IHCRHLMVWK IFAPRFIYEA LATFVSLPAL
1051 IVGYLLVLRI HRGVDTLIK RINKAKVH

HITS AT: 828-833

REFERENCE 1: 132:275067

L4 ANSWER 19 OF 28 REGISTRY COPYRIGHT 2002 ACS
RN 262988-39-6 REGISTRY
CN Protein (Drosophila melanogaster gene Mer) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN GenBank AE003512-derived protein GI 7293633
CI MAN
SQL 635

SEQ 1 MSPFGSKKNR SLSVRVSTFD SELEFKLEPR ASGQDLFDLV CRTIGLRESW
=====
51 YFGLQYVDTR SNVSWLKMEK RVRDQRVELH ASNNVYVFSF YAKFFPENVS
101 EELIQEITQH LFFLQVKQSI LSMDIYCRPE ASVLLASYAV HVQYGPYDYE
151 TYKDGMLÄGG ELLPKGVTDQ YQMTPEMWEE RIKTWYMDHE PMTRDEVEME
201 YLKIAQDLDL YGVNYFPITN KNKTKLWLGV TSVGLNIYDE RDKLTPKTTF
251 QWNEIRHVSF DDKKFTIRLV DAKVSNFIFY SQDLHINKMI LDLCKGNHDL
301 YMRRRKPDPM EIQQMKAQAK EEKQRRQIER KKFIKEKKLR EKAEEHERYEL
351 EKSMEHLQNE MRMANDALRR SEETKELYFE KSRVNEEQMQ LTECKANHFK
401 TEMDRLRERQ MKIEREKHDL EKKIRDADFY VHQLTVENDK REAETEKLKR
451 ELICAKMAER EATARLLEFL NSGRKSSTDs LLTASSVSHA ANTASSMAAI
501 STPSLITSSS TNDLETAGGA ELTTTHSSHYL VQGDNSSGIS DDFEPKEFIL
551 TDNEMEQITN EMERNHLDYL RNSKQVQSQL QTLRSEIAPH KIEENQSNLD
601 ILSEAQIKAG ENKYSTLKKL KSGSTKARVA FFEEL

HITS AT: 27-32

REFERENCE 1: 132:304167

L4 ANSWER 20 OF 28 REGISTRY COPYRIGHT 2002 ACS
RN 260386-80-9 REGISTRY
CN Protein NMASP (Neisseria meningitidis) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 2: PN: WO0012535 SEQID: 2 claimed protein
CI MAN
SQL 1253

SEQ 1 METLELEPRA SPPHEVALGL NLEVALGLNS ERGLGLYPR LAVALVALAS
=====
51 NILEGLNALA ALAPRALAPR ARGTHRGLNA SNGLYSERSE RASNALAGLT
101 HRASP SERAS PPRLEALAAAS PSERASPPRP HETYRGLPHE PHELYSARGL
151 EVALPRASNM ETPRGLILEP RGLNGLGLA AASPASPGLY GLYLEASNPH
201 EGLYSERGLY PHEILEILES ERLYSASPGL YTYRILELET HRASNTHRHI

09/627383

251 SVALVALTHR GLYMETGLYS ERILELYSVA LLELEASNAS PLYSARGGLT
301 YRTHRALALY SLEILEGLYS ERASPVALGL NSERASPVAL ALALELELYS
351 ILEASPALAT HRGLGLLEPR VALVALLYSI LEGLYASNPR LYSASPLEY
401 SPRGLYGLTR PVALALAALA ILEGGLYALAP RPHEGLYPHE ASPASNNSERV
451 ALTHRALAGL YVALSERALA LYSGLYARGS ERLEPRASNG LSERTYRTHR
=====

501 PRPHEILEGL NTHRASPVAL ALAILEASNP RGLYASNSER GLYGLYPRLE
551 PHEASNLELY SGLYGLNVAL VALGLYILEA SNSERGLNIL ETYRSERARG
601 SERGLYGLYP HEMETGLYIL ESERPHEALA ILEPRILEAS PVALALAMET
651 ASNVALALAG LGLNLELYSA SNTHRGLYLY SVALGLNARG GLYGLNLEGL
701 YVALILEILE GLNGLVALSE RTYRGLYLEA LAGLNSERPH EGLYLEASPL
751 YSALAGLYGL YALALEILEA LALYSILELE PRGLYSERPR ALAGLARGAL
801 AGLYLEARGA LAGLYASPIL EVALLESRL EASPGLYGLY GLILEARGSE
851 RSERGLYASP LEPRVALMET VALGLYALAI LETHRPRGLY LYSGLVALSE
901 RLEGLYVALT RPARGLYSGL YGLGLILETH RILELYSVAL LYSLEGLYAS
951 NALAALAGLH ISILEGLYAL ASERSERLYS THRASPLAL APRTYRTHRG
1001 LGLNGLNSE RGLYTHRPES ERVALGLSER ALAGLYILET HRLEGLNTHR
1051 HISTRASPS ERSERGLYGL YHISLEVALV ALVALARGVA LSERASPALA
1101 ALAGLARGAL AGLYLEARGA RGGLYASPGL ILELEALAVA LGLYGLNVAL
1151 PRVALASNAS PGLALAGLYP HEARGLYSAL AMETASPLYS ALAGLYLYSA
1201 SNVALPRLEL EILEMETARG ARGGLYASNT HRLEPHEILE ALALEASNLE
1251 GLN

HITS AT: 6-11, 483-488

REFERENCE 1: 132:204089

L4 ANSWER 21 OF 28 REGISTRY COPYRIGHT 2002 ACS
RN 253582-33-1 REGISTRY
CN Tumor suppressor protein (human gene AZ-2) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 4: PN: WO0000503 SEQID: 4 claimed protein
CI MAN
SQL 1219

SEQ 1 GTSDSPHGRW WSWDFAHTGV PGHVPRSTCA PSPQREVLTV PEANSEPWT
51 DTLGGERRPG VTAGILEMRN ALGNQSTPAP PTGEVADTPL EPGKVAGAAG
101 EAEGDITLST AETQACASGD LPEAGTTRTF SVVAGDLVLP GSCQDPACSD
151 KAPGMETAA LHGDSPARPQ QDKEQPGPER PIPAGDGKVC VSSPPEPDET
201 HDPKLQHLAP EELHTDRESP RPGPSMLPSV PKKDAPRVMK KVTSDETRGA
251 EGTESSPVAD DIIQPAAPAD LESPTLAASS YHSDVVGQVS TDLIAQRSSD
301 SEEAFETPES TTPVKAPPAP PPPPPEVIPE PEVSTQPPP EPGCGSETVP
351 VPDGPRSDSV EGSPFRPPSH PFSAVFDEDQ PIASSGTYNL DFDNIELVDT
401 FQTLEPRASD AKNQEGKVNT RRKSTDSVPI SKSTLSRSLS LQASDFDGAS
=====

451 SSGNPEAVAL APDAYSTGSS SASSTLKRK KPRPPSLKKK QTTKKPTETP
501 PVKETQQEPD EESLVPSGEN LASETKTESA KTEGPSPALL EETPLEPAVG
551 PKAACPLDSE SAEGVVPPAS GGGRVQNSPP VGRKTLPLTT APEAGEVTPS
601 DSGGQEDSPA KGLSVRLEFD YSEDKSSWDN QQENPPPTKK IGKKPVAKMP
651 LRRPKMKKTP EKLDNTPASP PRSPAEPNDI PIAKGTYTDF IDKWDPPNFN
701 PFSSTSCKMQE SPKLPQQSYN FDPDTCDESV DPFKTSKTP SSPSKSPASF
751 EIPASAMEAN GVDGDGLNKP AKKKKTPLKT VKKSPKRSPV SDPPSQDPTP
801 AATPETPPVI SAVVHATDEE KLAVTNQKWT CMTVDLEADK QDYPQPSDLS
851 TFVNETKFSS PTEELDYRNS YEIEYMEKIG SSLPQDDAP KKQALYLMFD
901 TSQESPVKSS PVRMSESPTP CSGSSFEETE ALVNTAAKNQ HPVPRGLAPN
951 QESHLQVPEK SSQKELEAMG LGTPSEAEI REAAHPTDVS ISKTALYSRI
1001 GTAEVEKPGW LLFQQPDLS ALQIARAEII TKEREVSEWK DKYEECSRREV
1051 MEMRKIVAEY EKTIAQMIED EQREKSVSHQ TVQQQLVLEKE QALADLNSVE
1101 KSLADLFRRY EKMKEVLEGF RKNEEVLKRC AQEYLSRVKK EEQRYQALKV

09/627383

1151 HAAEKLDTRAN AEIAQVRGKA QQEQAAHQAS LRKEQLRVDA LERTLEQKNK
1201 EIEELTKICD ELIAKMGKS

HITS AT: 404-409

REFERENCE 1: 132:74540

L4 ANSWER 22 OF 28 REGISTRY COPYRIGHT 2002 ACS
RN 250313-43-0 REGISTRY
CN Protein (Deinococcus radiodurans strain R1 gene DR1748) (9CI) (CA
INDEX NAME)
OTHER NAMES:
CN GenBank AE002016-derived protein GI 6459525
CI MAN
SQL 162

SEQ 1 MHPGPAILPF MDDLIQGRLG GADGYDIRCT IDGDKISGRA GGKLHGKDIE
51 LEITDRGVRC SVGQESVNIE LQEGERGNV GSQKLVLRGV DRVTGFMGP
101 IVGWNIVAAQQ QGESLQGQLG STVLGRVFSL DLGSAPGWVG TLVAVVAFYA
151 LEPRASMGQAQ AS
=====

HITS AT: 151-156

REFERENCE 1: 131:347336

L4 ANSWER 23 OF 28 REGISTRY COPYRIGHT 2002 ACS
RN 244613-54-5 REGISTRY
CN Myosin (human clone BACMYO1/BACMYO2 gene MYO9A isoform IXA) (9CI)
(CA INDEX NAME)
OTHER NAMES:
CN GenBank AF117888-derived protein GI 5732618
CN Myosin IXA (human clone BACMYO1/BACMYO2 gene MYO9A)
CI MAN
SQL 2548

SEQ 1 MNINDGGRRR FEDNEHTLRI YPGAISEGTL YCPIPARKNS TAAEVIESLI
51 NKLHLDKTKC YVLAEVKEFG GEEWILNPTD CPVQQMMLWP RMALENRLSG
101 EDYRFLLREK NLDGSIHYGS LQSWSLRVTEE RRRMMERGFL PQPQQKDFDD
151 LCSLPDLNEK TLLENLRDRF KHEKIYTYVG SILIVINPKF FLPIYNPKYV
201 KMYDNHQLGK PEPHIYAVAD VAYHAMLQRK KNQCIVISGE SGSGKTQSTN
251 FLIHHHTALS QKGFASGVEQ IILGAGPVLE AFGNAKTAHN NNSSRGKFI
301 QVNYQETGTV LGAYVEKYLL EKSRLVYQEH NERNYHVFYY LLAGASEDER
351 SAFHLKQPEE YHYLNQITKK PLRQSWDDYC YDSEPCFTV EGEDLRHDFE
401 RLQLAMEMVG FLPKTRRQIF SLLSAILHLG NICYKKKTYR DDSIDICNPE
451 VLPIVSELLE VKEEMLFEAL VTRKTVTVGE KLILPYKLAE AVTVRNSMAK
501 SLYSALFDWI VFRINHALLN SKDLEHNTKT LSIGVLDIFG FEDYENNSFE
551 QFCINFANER LQHYFNQHIF KLEQEYERTE GISWHNIDYI DNTCCINLIS
601 KKPTGLLHLL DEESNFPQAT NQTLDDKFHK QHEDNSYIEF PAVMEPAFII
651 KHYAGKVKYG VKDFREKNTD HMRPDIVALL RSSKNAFISG MIGIDPVAVF
701 RWAILRAFFR AMVAFREAGK RNIHRKTGHD DTAPCAILKS MDSFSFLQHP
751 VHQRSLIELQ RCKEEKYSIT RKNPRTPLSD LQGMNALNEK NQHDTFDIAW
801 NGRTGIRQSR LSSGTSLLDK DGIFANSTSS KLLERAHGL TRNKNFKSKP
851 ALPKHLLEVN SLKHLTRLTL QDRITKSLLH LHKKKKPPSI SAQFQASLSK
901 LMETLGQAEP YFVKCIRSNA EKLPLRFSDV LVLRQLRYTG MLETQVIRQS
951 GYSSKYSFQD FVSHFHVLLP RNIIPSKFNI QDFFRKINLN PDNYQVGKTM
1001 VFLKEQERQH LQDLLHQEV L RRIILLQRWF RVLLCRQHFL HLRQASVIIQ
1051 RFWRNYLNQK QVRDAAVQKD AFVMASAAL LQASWRAHLE RQRYLELRAA
1101 AIVIQQKWRD YYRRRHMAAI CIQARWKAYR ESKRYQEQRK KIILLQSTCR
1151 GFRARQRFKA LKEQLRRETQ PEVGLVNIKG YGSLEIQGSD PSEWEDCSFD

09/627383

1201 NRIKAIEECK SVIESNRISR ESSVDCLKES PNKQQERAQS QSGVDLQEDV
1251 LVRERPRSLE DLHQKKVGRA KRESRRMREL EQAIFSLELL KVRSLGGISP
1301 SEDRRWSTEL VPEGLQSPRG TPDSESSQGS LELLSYEEESQ KSKLESVISD
1351 EGDLQFPSPK ISSSPKFDSR DNALSASNET SSAEHLKDGTMKEMVVCSE
1401 SITCKPQLKD SFISNSLPTF FYIPQQDPLK TNSQLDTSIQ RNKLLENEDT
1451 AGEALTL DIN RETRTRYHCSG KDQIVPSLNT ESSNPVLKKL EKLNTKEER
1501 QKQLQQQNEK EMMEQIRQQT DILEKERKAF KTIEKPRIGE CLVAPSSYQS
1551 KQRVERPSSL LSLNTSNKGE LNLVGLSLSLK DAALAQKDSS SAHLPPKDRP
1601 VTVFFERKGS PCQSSTVKEL SKTDRMGTQL NVACKLSNNR ISKREHFRPT
1651 QSYSHNSDDL SREGNARPIF FTPKDNMSIP LVSKEALNSK NPQLHKEDEP
1701 AWKPVKLAGP GQRETSQRFS SVDEQAKLHK TMSQGEITKL AVRQKASDSD
1751 IRPQRAKMRF WAKGKQGEKK TTRVKPTTQS EVSPLFAGTD VIPAHQFPDE
1801 LAAYHPTPPL SPELPGSCRK EFKENKEPSP KAKRKRSVVKI SVALDSMHW
1851 QNDSVQIIAS VSDLKSMDEF LLKKVNDLDN EDSKKDTLVD VVFKKALKEF
1901 RQNIFSFYSS ALAMDDGKSI RYKDLYALFE QILEKTMRL QRDSLGEPSV
1951 RWWVNTFKVF LDEYMNNEFKT SDCTATKVK TERKKRKK TDLVEEHNGH
2001 IFKATQYSIP TYCEYCSSLI WIMDRASVCK LCKYACHKKC CLKTTAKCSK
2051 KYDPELSSRQ FGVELSRLLTS EDRTVPLVVE KLINYIEMHG LYTEGIYRKS
2101 GSTNKIKELR QGLDSTDASV NLDDYNHVI ASVFKQWLRD LPNPLMTFEL
2151 YEEFLRAMGL QERKETIRGV YSVIDQLSRT HLNTLERLIF HLVRIALQED
2201 TNRMSANALA IVFAPCILRC PDTTDPLQSV QDISKTTTCV ELIVVEQMNK
2251 YKARLKDISS LEFAENAKT RLSLIRRSMG KGRIRRGNP GPSSPVVVR
2301 PSVSDVSEET LTSEAAMETD ITEQQQAAMQ QEERVLTEQI ENLQKEKEEL
2351 TFEMLVLEPR ASDDETLESE ASIGTADSSE NLNMESEYAI SEKSERSLAL
===== ==
2401 SSLKTAGKSE PSSKLRKQLK KQQDSDLVVD SSVSSLCLSN TASSHGTRKL
2451 FQIYSKSPFY RAASGNEALG MEGPLGQTKF LEDKPQFISR GTFNPEKGKQ
2501 KLKNVKNSPQ KTKETPEGTV MSGRRKTVDP DCTSQQQLAL FGNNEFMV

HITS AT: 2357-2362

REFERENCE 1: 131:253834

L4 ANSWER 24 OF 28 REGISTRY COPYRIGHT 2002 ACS
RN 222964-43-4 REGISTRY
CN Myosin IXa (human clone BAC) (9CI) (CA INDEX NAME)
CI MAN
SQL 2548

SEQ 1 MNINDGGRRI FEDNEHTLRI YPGAISEGTLI YCPIPARKNS TAAEVIESLI
51 NKLHLDKTKC YVLAEVKEFG GEEWILNPTD CPVQQMMLWP RMALENRISG
101 EDYRFLLREK NLDGSIHYGS LQSWLRVTEE RRRMMERGFL PQPQQKDFDD
151 LCSLPDLNEK TLLENLRDRF KHEKIYTYVG SILIVINPK FLPIYNPKYV
201 KMYDNHQLGK PEPHIYAVAD VAYHAMLQRK KNQCIVISGE SGSGKTQSTN
251 FLIHHLTALS QKGFAASGVEQ IILGAGPVLE AFGNAKTAHN NNSSRGKFI
301 QVNYQETGTV LGAYVEKYLL EKSRLVYQEH NERNYHVFYY LLAGASEDER
351 SAFHLKQPEE YHYLNQITKK PLRQSWDDYC YDSEPCDFTV EGEDLRHDDE
401 RLQLAMEMVG FLPKTRRQIF SLLSAILHLG NICYKKKTYR DDSIDICNPE
451 VLPIVSELLE VKEEMLFEAL VTRKTVTGE KLILPYKLAE AVTVRNSMAK
501 SLYSALFDWI VFRINHALLN SKDLEHNTKT LSIGVLDIFG FEDYENNSFE
551 QFCINFANER LQHYFNQHIF KLEQEEYRTE GISWHNIDYI DNTCCINLIS
601 KKPTGLLHLL DEESNFPQAT NQTLDDKFHK QHEDNSYIEF PAVMEPAFII
651 KHYAGKVKYG VKDFREKNTD HMRPDIVALL RSSKNAFISG MIGIDPVAVF
701 RWAILRAFFR AMVAFREAGK RNIHRKTGHD DTAPCAILKS MDSFSFLQHP
751 VHQRSLEILQ RCKEEKYSIT RKNPRTPLSD LQGMNALNEK NQHDTFDIAW
801 NGRTGIRQSR LSSGTSLDK DGIFANSTSS KLLERAHGL TRNKNFKSKP
851 ALPKHLLEVN SLKHLTRLTL QDRITKSLH LHKKKKPPSI SAQFQASLSK
901 LMETLGQAEP YFVKCIRSNA EKPLPLRFSDV LVLRQLRYTG MLETVQIRQS
951 GYSSKYSFQD FVSHFHVLLP RNIIPSKFNI QDFFRKINLN PDNYQVGKTM

09/627383

1001 VFLKEQERQH LQDLLHQEVL RRIILLQRWF RVLLCRQHFL HLRQASVIIQ
1051 RFWRNYLNQK QVRDAAVQKD AFVMASAAL LQASWRAHLE RQRYLELRAA
1101 AIVIQQQKWRD YYRRRHMAAI CIQARWKAYR ESKRYQEQRK KIILLQSTCR
1151 GFRARQRFKA LKEQRIRETK PEVGLVNIKG YGSLEIQGSD PSEWEDCSFD
1201 NRIKAIIECK SVIESNRISR ESSVDCLKES PNKQQERAQS QSGVDLQEDV
1251 LVRERPRSLE DLHQKKVGRA KRESRRMREL EQAIFSLELL KVRSLGGISP
1301 SEDRRWSTEL VPEGLQSPRG TPDSESSQGS LELLSYEEQS KSKLESVISD
1351 EGDLQFPSPK ISSSPKFDSR DNALSASNET SSAEHLKDGT MKEMVVCSE
1401 SITCKPQLKD SFISNSLPTF FYIPQQDPLK TNSQLDTSIQ RNKLLENEDT
1451 AGEALTL DIN RETRYYHCSG KDQIVPSLNT ESSNPVLKKL EKLNTKEER
1501 QKQLQQQNEK EMMEQIRQQT DILEKERKAF KTIEKPRIGE CIVAPSSYQS
1551 KQRVERPSSL LSLNTSNKGE LNLVGLSLSLK DAALAQKDSS SAHLPPKDRP
1601 VTVFFERKGS PCQSSTVKEL SKTDRMGTQL NVACKLSNNR ISKREHFRPT
1651 QSYSHNSDDL SREGNARPIF FTPKDNMSIP LVSKEALNSK NPQLHKEDEP
1701 AWKPVKLAGP GORETSQRFS SVDEQAKLHK TMSQGEITKL AVRQKASDSD
1751 IRPQRAKMRF WAKGKQGEKK TTRVKPTTQS EVSPLFAGTD VIPAHQFPDE
1801 LAAYHPTPPL SPELPGSCRK EFKENKEPSP KAKRKRSVVKI SVALDSMHW
1851 QNDSVQIIAS VSDLKSMDEF LLKKVNLDN EDSKKDTLVD VVFKKALKEF
1901 RQNIFSFYSS ALAMDDGKSI RYKDLYALFE QILEKTMRL QRDSLGEESPV
1951 RVWVNTFKVF LDEYMNNEFKT SDCTATKVK TERKKRRKKE TDLVEEHNGH
2001 IFKATQYSIP TYCEYCSSLI WIMDRASVCK LCKYACHKKC CLKTTAKCSK
2051 KYDPELSSRQ FGVELSRLLTS EDRTVPLVVE KLINYIEMHG LYTEGIYRKS
2101 GSTNKIKELR QGLDTDAESV NLDDYNIHVI ASVFKQWLRD LPNPLMTFEL
2151 YEEFLRAMGL QERKETIRGV YSVIDQLSRT HLNTLERLIF HLVRIALQED
2201 TNRMSANALA IVFAPCILRC PDTTDPLQSV QDISKTTTCV ELIVVEQMNK
2251 YKARLKDISS LEFAENAKT RLSLIRRSMG KGRIRRGNYP GPSSPVVVR
2301 PSVSDVSEET LTSEAA METD ITEQQQAAMQ QEERVLTEQI ENLQKEKEEL
2351 TFEMLVLEPR ASDDETLESE ASIGTADSSE NLNMESEYAI SEKSERSLAL
===== ==
2401 SSLKTAGKSE PSSKLRKQLK KQQDSDLVVD SSVSSLCLSN TASSHGTRKL
2451 FQIYSKSPFY RAASGNEALG MEGPLGQTKF LEDKPQFISR GTFNPEKGKQ
2501 KLKNVKNSPQ KTKETPEGTV MSGRRKTVDP DCTSNNQLAL FGNNEFMV

HITS AT: 2357-2362

REFERENCE 1: 130:292458

L4 ANSWER 25 OF 28 REGISTRY COPYRIGHT 2002 ACS
RN 221651-87-2 REGISTRY
CN GTPase-activating protein Myr-7 (Rattus norvegicus gene myo9a Rho
protein-specific) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN GenBank AJ001713-derived protein GI 3955026
CN Myosin-RhoGAP protein Myr 7 (rat gene myo9a)
CI MAN
SQL 2626

SEQ 1 MNVSDGGRRR FEDNEHTLRI YPGTISEGTI YCPIPARKNS TAAEVIDSLI
51 NRLHLDKTKC YVLAEVKEFG GEEWILNPTD CPVQRMMWLP RMALENRLSG
101 EDYRFLLREK NLDGSIHYGS LQSWLRVTEE RRRMMERGFL PQPQQKDFDD
151 LCSLPDLNEK TLLENLRNRF KHEKIYTYVG SILIAINPKF FLPIYNPKYV
201 KMYDNHOLGK LEPHIYAVAD VAYHAMLQRK KNQCIVVISGE SGSGKTQSTN
251 FLIHHHTALS QKGFASGVEQ IILGAGPVLE AFGNAKTAHN NNSSRGKFI
301 QVNYQETGTV LGAYVEKYLL EKSRLVYQEH NERNYHVFYY LLAGASEEER
351 LAFHLKQPEE YHFLNQITKK PLRQSWDDYC YDSEPCDCFTV EGEDLRHDFE
401 RLQLAMEMVG FLPKTRRQIF SLLSAILHLG NISYKKKTYR DDSIDICNPE
451 VLPIVSELLE VKEEMLFEAL VTRKTVTVGE KLILPYKLAE AVTVRNSMAK
501 SLYSALFDWI VFRINHALLN SKDLEKDTKT LSIGVLDIFG FEDYENNSFE
551 QFCINFANER LQHYFNQHIF KLEQEEYRTE GISWHNIDYI DNTCCINLIS

09/627383

601 KKPTGLLHLL DEESNFPQAT NQTLDDKFKH QHEENSYIEF PAVMEPAFII
651 KHYAGKVKYG VKDFREKNTD HMRPDIVALL RSSRNAFVSG MTGIDPVAVF
701 RWAVLRAFFR AVVAFREAGK RHIQRKSGHD DTPCTILKS MDSFSFLQHP
751 VHQRSLIELQ RCKEEKYSIT RKNPRTPLSD LQGMNTLNEK NQHDTFDIAW
801 NVRTGIRQSR LPTNNTSLLD KDGIFANSAS SKLLERAHGI LTRNKNFRSK
851 PVLPKHLLEV NSLKHLTRLT LQDRITKSLL HLHKKKKPPS ISAQFQVSL
901 KLMETLDQAE PYFVKCIRSN AEKLPLRFSD ALVLRQLRYT GMLETVRIRQ
951 SGYSSKYSFQ DFVSHFHVLL PQHIIPSKFN IQDFFRKINI NPDNYQVGKT
1001 MVFLKEHERQ HLQDLLHQEV LRRIILLQRW FRVLLSRQOF LHLRQASVII
1051 QRFWRNLYLNQ KQVRNAAVEK DAFIMASAAS LLQASWRAHL ERQRYLELRA
1101 AAVIIQQRWR ELCRRRHRAA TCIQSRWRGY RQSKKYKEQR NKİİLLQSIY
1151 RGFRARQRYK ALKEERLKET KLEHGLAQIK TCGPLEIQGS DPSEWEDRSF
1201 ANRVKAIEEC KSVIESNRIS RESSMDFSKE SPDQKQERGR SQSGTDLQGD
1251 VIVRQRPKSL EDLHQKKVGR AKRESRRMRE LEQAIIFSSEL LKVRSLGGMS
1301 PSEERRWSTE LMPEGLQSPQ GTPDSESSQG SLELLTCDEN QKSKPESLIL
1351 DDGELKISSP STFTNPKFDS QNNALSASSE TSSTFSGKGA SSDSEHLKNG
1401 TAEELKLVYSS QPITCKSQLR DSFVSSLPT FFYIPHQEPL KTSSQLDTSI
1451 QRNKLPERET TLKTTLTLDI NREARKCQFS GQVTPLPNPD SCTLVKKLEK
1501 LNIEKEKROK QLQQQNEKEM MEQIROQTDI LEKERKAFKT IEQSRTEASL
1551 LAPSFYQSRQ KVERPSSLHI QNTPSKGEAG VLGSPSALAT KDSPSIHLPP
1601 KDRPVTLFFE RKGSPCQSRV VKELTKTERM GTQHDAACRL SNNHNTEREH
1651 FKSTHSYSHR SDDPSREGSS RPIFFTPKDN VITPLVHSGN PQVHKQDEPA
1701 WKSCLAGPGQ REVARPAHKK KARMARTRSD FLTRGTFADG EGDTEEDDYD
1751 DIIEPLLSSLD QASHSELGPV SSLGQASHSD SEMTSQRFSS VDEQARLHK
1801 MSQGEITKLA GRQKSSLDI RPQRRAKMRFW AKGKQGEKKT TRVKPAPQSE
1851 VSSLFAGSDV TPVHPFSDEL TQYHPTPPPLS PELPGSCRKE FKENKEPSPK
1901 AKRKRGVKIS SVALDSMHQ NDSVQIIASA NDLKSMDEF L LKKMNDLDNE
1951 DSKKDTLVDV VFKKALKEFR QNIFSSYSSA LAMDDGKSIR YKDLYALFEQ
2001 ILEKTMRFEQ RDWNESPVRV WVNTFKVFLD EYMNNEFKTLD STAPKVLKTE
2051 RKKRRKKETD LVEEHNGHMF KATQYSIPTY CEYCSSLIWI MDRASVCKLC
2101 KYACHKKCCL KTTAKCSKKY DPELSSRQFG VELSRLTSED RAVPLVVEKL
2151 INYIEMHGLY TEGIYRKSGS TNKIKELRQG LDTDAESVNL DDYNINHVIAS
2201 VFKQWLRDLP NPLMTFELYE EFLRAMGLQE RKETIRGVYS VIDQLSRTHL
2251 STLERLIFHL VRIALQEDTN RMSANALAAIV FAPCILRCPD TTDPLQSVQD
2301 ISKTTTCVEL IVVEQMNKYK ARLKDISSLE FAENKAKTRL SLIRRSMKP
2351 LIAVRFMSIT RSSVSGKGRL HRGSHPNPSS PVIVRLPSMS DVPEETLTSE
2401 TAMDTDVTDQ QQAAMQQEEK VLTEQIENLQ KEKEELTFEM LVLEPRASDD
=====

2451 EALESSEASIG TADSSENLN M DPEERSLALS SLKAAGKSEP SSKFRKQLRK
2501 QPDSDLDSVSS SVSSCLSN TT SSHGTRKRFQ IYSKSPFYRA ASACEAQGME
2551 GPLGQAKSLE DRPQFISRG RT FNPEKGKQKL KNVKNSPQKT KETPEGTVSS
2601 GRKKTVDS DC SSTQQLPLFG NNEFMV

HITS AT: 2443-2448

REFERENCE 1: 130:265212

L4 ANSWER 26 OF 28 REGISTRY COPYRIGHT 2002 ACS
RN 218778-68-8 REGISTRY
CN 178-273-Protein Zneul (human neuro-growth factor-like fragment)
(9CI) (CA INDEX NAME)

OTHER NAMES:

CN Protein Zneul (human neuro-growth factor-like HSMHC3W5A-like (HSM2)
domain)
CI MAN
SQL 256

SEQ 1 PRLYSGLYGL YPRPRARGVA LALAPRASNP RTHRGLYVAL ASPSERALAM
51 ETLYSGLGLV ALGLNARGLE GLNSERARGV ALASPLELEG LGLLYSLEGL

09/627383

101 NLEVALLEAL APRLEHISSE RLEALASERG LNALALEGLH ISGLYLEPRA
=====
151 SPPRGLYSER LELEVALHIS SERPHEGLNG LNLEGLYARG ILEASPSERL
=

201 ESERGLGLNI LESERPHELE GLGLGLNLEG LYSERCYSSE RCYSLYSLYS
251 ASPSER

HITS AT: 146-151

REFERENCE 1: 130:77730

L4 ANSWER 27 OF 28 REGISTRY COPYRIGHT 2002 ACS
RN 218778-65-5 REGISTRY
CN 20-104-Protein Zneul (human neuro-growth factor-like fragment) (9CI)
(CA INDEX NAME)
OTHER NAMES:
CN Protein Zneul (human neuro-growth factor-like HSMHC3W5A-like (HSM1)
domain)
CI MAN
SQL 708

SEQ 1 THRGLHISAL ATYRARGPRG LYARGARGVA LCYSALALVAL ARGALAHISG
51 LYASPPRVAL SERGLSERPH EVALGLNARG VALTYRGLNP RPHELETHRT
101 HRCYSASPGL YHISARGALA CYSSERTHRT YRARGTHRIL ETYRARGTHR
151 ALATYRARGA RGSERPRGLY LEALAPRALA ARGPRARGTY RALACYSCYS
201 PRGLYTRPLY SARGTHRSE RGLYLEPRGLY ALACYSGLYA LAALALAILECY
251 SGLNPRPRCY SARGASNGLY GLYSERCYSV ALGLNPRLY ARGCYSARGC
301 YSPRALAGLY TRPARGGLY SPHTRCYSGL NSERASPVAL ASPGLCYSS
351 RALAARGARG GLYGLYCYSR RGLNARGCYS VALASNTHRA LAGLYSERTY
401 RTRPCYSGLN CYSTRPGLGL YHISSERLES ERAALAASPGL YTHRLECYSV
451 ALPRLYSGLY GLYPRPRARG VALALAPRAS NPRTHRGGLYV ALASPSEL
501 AMETLYSGLG LVALGLNARG LEGLNSERAR GVALASPLEL EGLGLLYSLE
551 GLNLEVALLE ALAPRLEHIS SERLEALASE RGLNALALEG LHISGLYLEP
=====

601 RASPPRGLYS ERLELEVALH ISSERPHEGL NGLNLEGLYA RGILEASPSE
====

651 RLESERGLGL NILESERPHE LEGLGLGLNL EGLYSERCYS SERCYSLYSL
701 YSASPSEL

HITS AT: 598-603

REFERENCE 1: 130:77730

L4 ANSWER 28 OF 28 REGISTRY COPYRIGHT 2002 ACS
RN 178535-96-1 REGISTRY
CN Merlin (Drosophila melanogaster moesin-ezrin-radixin-like) (9CI)
(CA INDEX NAME)
CI MAN
SQL 636

SEQ 1 MSPFGSKKNR SLSVRVSTFD SELEFKLEPR ASGQDLFDLV CRTIGLRESW
===== ==
51 YFGLQYVDTR SNVSWLKMEK RVRDQRVELH ASNNVYVFSF YAKFFPENVS
101 EELIQEITQH LFFLQVKQSI LSMDIYCRPE ASVLLASYAV HVQYGPYDYE
151 TYKDGMLAGG ELLPKGVTDQ YQMTPEMWEE RIKTWYMDHE PMTRDEVEME
201 YLKIAQDLM YGVNYFPITN KNKTKLWLGV TSVGLNIYDE RDKLTPKTTF
251 QWNEIRHVSF DDKKFTIRLV DAKVSNFIFY SQDLHINKMI LDLCKGNHDL
301 YMRRRKPDPM EIQQMKAQAK EEKQRRQIER KKFIKEKKLR EKAEEHERYEL
351 EKSMEHLQNE MRMANDALRR SEETKELYFE KSRVNEEQMQ LTECKANHFK
401 TEMDRLRERQ MKIEREKHDL EKKIRDADFY VHQLTVENDK REAETEKLK

09/627383

451 ELICAKMAER EATARLLEFL NSGRKSSTDs LLTASSVSHA ANTASSMAAI
501 STPSLITSSS TNDLETAGGA ELTTHSSHYL VQGDNSSGIS DDFEPKEFIL
551 TDNEMEQITN EMERNHLDYL RNSKQVQSQL QTLRSEIAPH KIEENQSNLD
601 ILSEAQIKAG ENKYSTLKKL KSGSTKARVA FFEELX

HITS AT: 27-32

REFERENCE 1: 125:82238

(FILE 'HCAPLUS' ENTERED AT 15:42:25 ON 07 JUN 2002)
L5 6517 SEA FILE=HCAPLUS ABB=ON PLU=ON GFP(S)GREEN OR GREEN
FLUORESC? PROTEIN
L6 1795 SEA FILE=HCAPLUS ABB=ON PLU=ON L5 AND (MUTAT? OR
MUTAGEN? OR MUTANT OR POLYMORPH? OR POLY MORPH?)
L7 5 SEA FILE=HCAPLUS ABB=ON PLU=ON L6 AND (SER147PRO OR
((SER OR SERINE) (S)147 OR SER147 OR SERINE147) (S) (PRO OR
PROLINE) OR SERINE147PROLINE)

L8 5 L7 NOT L2

L8 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:187032 HCAPLUS
TITLE: Why do folding **mutations** decrease the
thermosensitivity of **Green**
Fluorescent Proteins?
AUTHOR(S): Zimmer, Marc; Fedele, Flavia
CORPORATE SOURCE: Chemistry, Connecticut College, New London, CT,
06320, USA
SOURCE: Abstracts of Papers, 223rd ACS National Meeting,
Orlando, FL, United States, April 7-11, 2002
(2002), CHED-401. American Chemical Society:
Washington, D. C.
CODEN: 69CKQP
DOCUMENT TYPE: Conference; Meeting Abstract
LANGUAGE: English

AB **Green Fluorescent Protein** is a spontaneously fluorescent sol. globular protein isolated from jellyfish (*Aequorea victoria*). The efficiency with which newly synthesized GFP folds into the fluorescent active form is temp. dependent, which causes difficulty in the use of GFP. Recently it was shown that **mutation** of the **serine** residue at position **147** to a **proline** results in a redn. of the temp. sensitivity of GFP. The **mutated** variant is able to efficiently mature at temps. as high as 37 .degree.C. We have attempted to det. through computational methods whether the lower thermosensitivity of the S147P **mutant** is due to a better folding of the b-sheets in the b barrel of GFP and therefore to a tighter folding of the residues around the chromophore region of GFP. Our results show that there is no significant difference between the folding pattern of the b-barrel in the wild-type and **mutant** GFP but the chromophore region is more tightly preorganized for autocatalytic cyclization in the S147P **mutant**.

L8 ANSWER 2 OF 5 HCAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:473042 HCAPLUS
DOCUMENT NUMBER: 135:89517
TITLE: A bioluminescence resonance energy transfer (BRET) system with broad spectral resolution

-key terms

09/627383

between donor and acceptor emission wavelengths
and its use
INVENTOR(S): Joly, Erik
PATENT ASSIGNEE(S): Biosignal Packard Inc., Can.
SOURCE: PCT Int. Appl., 132 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001046691	A1	20010628	WO 2000-CA1516	20001222
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:			CA 1999-2291968	A 19991222
			CA 2000-2314861	A 20000802

AB The present invention provides a bioluminescence resonance energy transfer (BRET) detection system characterized by a broad spectral resoln. between donor and acceptor emission wavelengths. The broad spectral resoln. between the emission wavelength of the bioluminescent donor protein and the fluorescent acceptor mol. results in an increased signal-to-base ratio and dynamic range in comparison with a basic BRET system. A BRET apoptosis sensor was prep'd. by recombinantly prep'd. **mutant green fluorescent protein** GFP1 fused with a linker peptide contg. a caspase-3 cleavage site and fused with **mutant** Renilla luciferase (Rluc). Upon induction of apoptosis, caspase-3 cleaves the linker, sepg. the GFP1 from Rluc causing the BRET ratio to decrease over time.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 3 OF 5 HCPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1999:324955 HCPLUS
DOCUMENT NUMBER: 131:155431
TITLE: S147P **green fluorescent protein**: a less thermosensitive **green fluorescent protein** variant
AUTHOR(S): Kimata, Yukio; Lim, Chun Ren; Kohno, Kenji
CORPORATE SOURCE: Research and Education Center for Genetic Information, Nara Institute of Science and Technology, Nara, 630-01, Japan
SOURCE: Methods in Enzymology (1999), 302(Green Fluorescent Protein), 373-378
CODEN: MENZAU; ISSN: 0076-6879

09/627383

PUBLISHER: Academic Press
DOCUMENT TYPE: Journal
LANGUAGE: English
AB A new **green fluorescent protein** (GFP) variant is described in which **serine-147 is mutated to proline**. The S147P mutation alters the maturation efficiency of GFP at 37.degree. and causes a 5-nm shift in the peak of excitation. This novel mutation may be useful to enhance the fluorescence properties of other GFP variants at 37.degree.. (c) 1999 Academic Press.
REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1998:585457 HCAPLUS
DOCUMENT NUMBER: 129:241552
TITLE: Recombinant preparation of **green-fluorescent protein** mutant of *Aequorea victoria*
INVENTOR(S): Kono, Kenji; Takeda, Katsuo; Hasegawa, Mamoru
PATENT ASSIGNEE(S): Dinabeck Laboratory K. K., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 11 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 10234382	A2	19980908	JP 1997-62370	19970227

AB A **green-fluorescent protein** mutant having substitution mutations at 65-Ser.fwdarw.Thr and 147-Ser.fwdarw. Pro is prep'd. by expression of the **mutagenized** gene in transgenic host cells. The **mutant** is able to generate fluorescence at high temp. (37.degree.).

L8 ANSWER 5 OF 5 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1997:188644 HCAPLUS
DOCUMENT NUMBER: 126:260574
TITLE: A novel mutation which enhances the fluorescence of **green fluorescent protein** at high temperatures
AUTHOR(S): Kimata, Yukio; Iwaki, Masaharu; Lim, Chun Ren; Kohno, Kenji
CORPORATE SOURCE: Research and Education Center for Genetic Information, Nara Institute of Science and Technology, Nara, 630-01, Japan
SOURCE: Biochem. Biophys. Res. Commun. (1997), 232(1), 69-73
CODEN: BBRCA9; ISSN: 0006-291X
PUBLISHER: Academic
DOCUMENT TYPE: Journal
LANGUAGE: English

AB **Green fluorescent protein (GFP)**

) from *Aequorea victoria* is widely used as a marker of gene expression and protein localization in living cells from prokaryotes to eukaryotes. However, the total fluorescent signal from wild-type GFP is very weak when expressed in cells cultured at 37.degree. compared to 30.degree. or below. This characteristic makes GFP poorly suited to use as a marker in mammalian cells. Here the authors describe a new variant of GFP which carries a substitution of **Ser147** to **Pro** (S147P GFP) and which emits a stronger fluorescent signal than the wild-type GFP at high temp. When S147P is combined with the **Ser65** to **Thr mutation** (S65T GFP), the resulting double **mutant** emits fluorescence which is several-fold stronger than GFP with a single S65T modification in both bacterial or mammalian cells. This S147P **mutation** should be useful for constructing new GFP variants which stably emit strong fluorescence at a wide range of culturing temps.

L5 6517 SEA FILE=HCAPLUS ABB=ON PLU=ON GFP(S)GREEN OR GREEN
FLUORESC? PROTEIN
L6 1795 SEA FILE=HCAPLUS ABB=ON PLU=ON L5 AND (MUTAT? OR
MUTAGEN? OR MUTANT OR POLYMORPH? OR POLY MORPH?)
L9 8 SEA FILE=HCAPLUS ABB=ON PLU=ON L6 AND (SER147PRO OR
((SER OR SERINE)(S)147 OR SER147 OR SERINE147)(S)(PRO OR
PROLINE) OR SERINE147PROLINE OR S147P)

=> s 19 not (12 or 18)
L10 3 L9 NOT (L2 OR L8)

L10 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2001:733485 HCAPLUS
DOCUMENT NUMBER: 136:66712
TITLE: Functional correlation between the nuclear
localization of Fht1p and its flocculation and
heat tolerance activities in budding yeast
Saccharomyces cerevisiae
AUTHOR(S): Iha, Hidekatsu; Tezuka, Hideo; Yaguchi, So-ichi;
Tsurugi, Kunio
CORPORATE SOURCE: Department of Biochemistry, Yamanashi Medical
University, Yamanashi, Japan
SOURCE: Journal of Biomedical Science (Basel,
Switzerland) (2001), 8(5), 416-420
CODEN: JBCIEA; ISSN: 1021-7770
PUBLISHER: S. Karger AG
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Fht1p is involved in the flocculation and heat tolerance machinery of budding yeast *Saccharomyces cerevisiae*. Despite knowledge of its involvement in those phenotypes, a precise mechanism has yet to be discovered. To this end, the authors monitored the relationship between subcellular localization of Fht1p and its flocculation or heat tolerance function using newly developed expression vectors with a recombinant **green fluorescent protein** (GFP; S65T/S147P) of *Aequorea victoria* added at both the N- and C-terminus of Fht1p. The main fluorescent signal of the GFP tagged with either a wild-type Fht1p or **mutants** which preserve their flocculation function was

09/627383

detected in the nucleus, whereas signals of functionless
mutants were dispersed to the cytoplasm.

REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE
FOR THIS RECORD. ALL CITATIONS AVAILABLE
IN THE RE FORMAT

L10 ANSWER 2 OF 3 HCPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2000:595996 HCPLUS
DOCUMENT NUMBER: 133:263439
TITLE: A flexible single-step detection of blotted
antigen using a fusion protein between protein A
and **green fluorescent**
protein
AUTHOR(S): Aoki, Takashi; Miyashita, Mamiko; Fujino,
Hiroyoshi; Watabe, Hiroyuki
CORPORATE SOURCE: Department of Biochemistry, Faculty of
Pharmaceutical Sciences, Health Sciences
University of Hokkaido, Hokkaido, 061-0293,
Japan
SOURCE: Bioscience, Biotechnology, and Biochemistry
(2000), 64(7), 1547-1551
CODEN: BBBIEJ; ISSN: 0916-8451
PUBLISHER: Japan Society for Bioscience, Biotechnology, and
Agrochemistry
DOCUMENT TYPE: Journal
LANGUAGE: English
AB **A green fluorescent protein**
mutant (S147P GFP) was fused with
protein A and expressed in *Escherichia coli*. This fusion protein
(PA-GFP147) was used in immunoblotting studies as a new detection
system, designated as "flexible single-step detection (FSSD)". In
FSSD, the detection of blotted antigen was done in one step, and the
antigen-antibody reaction can be monitored by UV-irradn. in real
time. The reaction time, therefore, can be flexibly controlled by
monitoring the green fluorescence.
REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE
FOR THIS RECORD. ALL CITATIONS AVAILABLE
IN THE RE FORMAT

L10 ANSWER 3 OF 3 HCPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1999:271796 HCPLUS
DOCUMENT NUMBER: 131:141604
TITLE: Imaging Cells in the Developing Nervous System
with Retrovirus Expressing Modified
Green Fluorescent
Protein
AUTHOR(S): Okada, Ami; Lansford, Rusty; Weimann, James M.;
Fraser, Scott E.; McConnell, Susan K.
CORPORATE SOURCE: Department of Biological Sciences, Stanford
University, Stanford, CA, 94305, USA
SOURCE: Experimental Neurology (1999), 156(2), 394-406
CODEN: EXNEAC; ISSN: 0014-4886
PUBLISHER: Academic Press
DOCUMENT TYPE: Journal
LANGUAGE: English
AB To visualize the movements of cells and their processes in
developing vertebrates, we constructed replication-incompetent
retroviral vectors encoding **green fluorescent**

protein (GFP) that can be detected as a single integrated copy per cell. To optimize GFP expression, the CMV enhancer and avian .beta.-actin promoter were incorporated within a retrovirus construct to drive transcription of red shifted (F64L, S65T) and codon-modified GFP (EGFP), EGFP tagged with GAP-43 sequences targeting the GFP to the cell membrane, or EGFP with addnl. **mutations** that increase its ability to fold properly at 37.degree. (S147P or V163A, S175G). We have used these viruses to efficiently mark and follow the developmental progression of a large population of cells in rat neocortex and whole avian embryos. In the chick embryo, the migration and development of GFP-marked neural crest cells were monitored using time-lapse videomicroscopy. In the neocortex, GFP clearly delineates the morphol. of a variety of neuronal and glial phenotypes. Cells expressing GFP display normal dendritic morphologies, and infected cells persist into adulthood. Cortical neurons appear to form normal local axonal and long-distance projections, suggesting that the presence of cytoplasmic or GAP-43-tagged GFP does not significantly interfere with normal development. (c) 1999 Academic Press.

REFERENCE COUNT: 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

(FILE 'MEDLINE, BIOSIS, EMBASE, WPIDS, CONFSCI, SCISEARCH, JICST-EPLUS, JAPIO' ENTERED AT 15:46:35 ON 07 JUN 2002)

L11 21 S L9
L12 9 DUP REM L11 (12 DUPLICATES REMOVED)

L12 ANSWER 1 OF 9 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
ACCESSION NUMBER: 2002:239062 BIOSIS
DOCUMENT NUMBER: PREV200200239062
TITLE: Application of **green fluorescent protein** to affinity electrophoresis; affinity of IgG-binding domain C from streptococcal protein G to mouse IgG1.
AUTHOR(S): Kazama, Hitoshi (1); Yamada, Keiko; Aoki, Takashi; Watabe, Hiroyuki
CORPORATE SOURCE: (1) Department of Biochemistry, Faculty of Pharmaceutical Sciences, Health Sciences University of Hokkaido, 1757 Kanazawa, Ishikari-Tobetsu, Hokkaido, 061-0293: kazama@hoku-iryo-u.ac.jp Japan
SOURCE: Biological & Pharmaceutical Bulletin, (February, 2002) Vol. 25, No. 2, pp. 168-171. print.
ISSN: 0918-6158.
DOCUMENT TYPE: Article
LANGUAGE: English
AB Affinity electrophoresis (AEP) using **green fluorescent protein (GFP)** was studied. We constructed a fusion protein that linked S147PGFP and IgG binding domain C from streptococcal protein G (GFP-SpGC). The affinity of GFP-SpGC for mouse IgG1 was measured. The AEP using GFP does not require a staining step after electrophoresis, and was successful with a non-purified sample. Therefore, this method is simple and useful for measuring many samples such as those used in **mutational** studies.

L12 ANSWER 2 OF 9 WPIDS (C) 2002 THOMSON DERWENT

09/627383

ACCESSION NUMBER: 2001-408713 [43] WPIDS
DOC. NO. NON-CPI: N2001-302445
DOC. NO. CPI: C2001-123795
TITLE: Bioluminescence resonance energy transfer system useful to monitor enzyme activity, comprises bioluminescent donor protein attached to first molecule and fluorescent acceptor molecule attached to second molecule.
DERWENT CLASS: B04 D16 S03
INVENTOR(S): JOLY, E
PATENT ASSIGNEE(S): (BIOS-N) BIOSIGNAL PACKARD INC
COUNTRY COUNT: 94
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2001046691	A1	20010628 (200143)*	EN	132	
RW:	AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC				
MW	MZ NL OA PT SD SE SL SZ TR TZ UG ZW				
W:	AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE				
DK	DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG				
KP	KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ				
PL	PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN				
YU	ZA ZW				
AU 2001023348	A	20010703 (200164)			

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2001046691	A1	WO 2000-CA1516	20001222
AU 2001023348	A	AU 2001-23348	20001222

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 2001023348	A	Based on WO 200146691

PRIORITY APPLN. INFO: CA 2000-2314861 20000802; CA 1999-2291968
19991222

AN 2001-408713 [43] WPIDS

AB WO 200146691 A UPAB: 20010801

NOVELTY - A bioluminescence resonance energy transfer (BRET) system (I) comprising a bioluminescent donor protein (BDP) attached to a first molecule or modulator, and a fluorescent acceptor molecule (FAM) attached to a second molecule or modulator, where FAM can accept the energy from the BDP when they are associated, in the presence of the appropriate substrate.

DETAILED DESCRIPTION - In (I), a physical change in the modulator(s) influences the energy transfer efficiency between the BDP and the FAM, and (I) has a broad spectral resolution of at least 80 nm between the peaks of BDP and FAM emission spectra.

An INDEPENDENT CLAIM is also included for production of (I).

USE - (I) is useful to monitor protein-protein interactions or enzyme activity in vitro or in vivo (claimed). (I) is useful for in vitro and in vivo detection methods, and in assays to detect molecular changes in a wide variety of applications such as drug

09/627383

discovery, analyte screening, second messenger screening, drug screening, diagnosis, genotoxicity, identification of gene function, gene discovery, and proteomics. (I) is useful to study receptorimerization/multimerization, to characterize orphan receptors, to identify ligands for orphan receptors, for detecting interaction which occur as a consequence of receptor signaling, and to study the effect of additional molecule on receptor function.

ADVANTAGE - (I) provides an improved signal-to-base ratio (S/B) and dynamic range (DR) over a basic BRET system. (I) is readily adaptable to methods of automation and high throughput screening.

Dwg.0/34

L12 ANSWER 3 OF 9 WPIDS (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: 2001-159852 [16] WPIDS
DOC. NO. CPI: C2001-047604
TITLE: New affinity fluorescent protein comprising a modified fluorescent protein having a heterologous amino acid sequence and a ligand-activated protein binding site, for detecting target ligand in a mixture of macromolecules or in a cell.
DERWENT CLASS: B04 D16
INVENTOR(S): EHRLICH, D J; FREYSON, Y; MATSUDAIRA, P T; ZHONG, Q
PATENT ASSIGNEE(S): (WHED) WHITEHEAD INST BIOMEDICAL RES
COUNTRY COUNT: 20
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2001009177	A2	20010208	(200116)*	EN	44
RW: AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE					
W: CA JP					

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2001009177	A2	WO 2000-US20619	20000728

PRIORITY APPLN. INFO: US 1999-146438P 19990729

AN 2001-159852 [16] WPIDS

AB WO 200109177 A UPAB: 20010323

NOVELTY - An affinity fluorescent protein (aFP) comprising a modified fluorescent protein molecule with a **mutated** fluorescent protein molecule and a heterologous amino acid sequence having a ligand-activated protein binding site, is new.

DETAILED DESCRIPTION - A new affinity fluorescent protein (aFP) comprises a modified fluorescent protein molecule with a **mutated** fluorescent protein molecule and a heterologous amino acid sequence having a ligand-activated protein binding site. The modified fluorescent protein molecule displays an altered spectral property when the binding site is engaged with ligand relative to the spectral property displayed when the binding site is not engaged by ligand.

INDEPENDENT CLAIMS are also included for the following:

(1) an aFP expression cassette or expression vector comprising a modified **green fluorescent protein** (**GFP**) nucleic acid sequence which is **mutated** and

operatively linked to expression control sequences, where the modified GFP sequence comprises a recombinant peptide having restriction endonuclease sites introduced at a location of the GFP molecule selected from between Gln 157 and Lys 158, Glu 172 and Asp 173, or both locations;

(2) a host cell comprising a recombinant nucleic acid having expression control sequences operatively linked to a nucleotide sequence encoding an aFP, which has a modified or **mutated** GFP molecule and a heterologous amino acid sequence functioning as a ligand-activated protein binding site, and which displays an altered spectral property when the binding site is engaged with ligand relative to the spectral property displayed when the binding site is not engaged by ligand;

(3) detecting the presence of a target ligand in a mixture of macromolecules by:

(a) contacting a sample with an aFP comprising a binding site for the target ligand;

(b) exciting the aFP with light; and

(c) measuring the fluorescent property that differs as a result of ligand activation of the aFP; and

(4) detecting the occurrence of a target ligand in a cell by:

(a) introducing into the cell an aFP comprising a binding site for the target ligand;

(b) exciting the aFP present in the cell with light; and

(c) detecting the fluorescence pattern due to ligand activation of the affinity fluorescent protein in the cell and comparing it to the fluorescence pattern in a control cell, where the fluorescence pattern determines the occurrence of the target ligand in the cell.

USE - The aFP is useful for:

(i) detecting target ligand in a mixture of macromolecules or in a cell;

(ii) for detecting and monitoring a range of in vitro and in vivo biological activities which include specific molecular processes in cells, cellular physiology, and the detection, quantification and/or purification of a target ligand from a wide variety of samples; and

(iii) use as a substitute for reporter-molecule labeled monoclonal or polyclonal antibodies.

The aFP can covalently bind a variety of molecules (e.g. natural, synthetic, biological, non-biological, organic, inorganic, protein, non-protein small or large), and can function both as molecular recognition groups and as molecular biosensors which are capable of sensing and reporting the interaction of a binding site with its cognate ligand.

Dwg.0/11

L12 ANSWER 4 OF 9	MEDLINE	DUPLICATE 1
ACCESSION NUMBER:	2001500401	MEDLINE
DOCUMENT NUMBER:	21434002	PubMed ID: 11549884
TITLE:	Functional correlation between the nuclear localization of Fht1p and its flocculation and heat tolerance activities in budding yeast <i>Saccharomyces cerevisiae</i> .	
AUTHOR:	Iha H; Tezuka H; Yaguchi S; Tsurugi K	
CORPORATE SOURCE:	Department of Biochemistry, Yamanashi Medical University, Yamanashi, Japan..	
SOURCE:	hiha@swallow.res.yamanashi-med.ac.jp	
	JOURNAL OF BIOMEDICAL SCIENCE, (2001 Sep) 8 (5)	

09/627383

416-20.

Journal code: 9421567. ISSN: 1021-7770.

PUB. COUNTRY: Switzerland

Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 200112

ENTRY DATE: Entered STN: 20010911

Last Updated on STN: 20020124

Entered Medline: 20011231

AB Fht1p is involved in the flocculation and heat tolerance machinery of budding yeast *Saccharomyces cerevisiae*. Despite knowledge of its involvement in those phenotypes, a precise mechanism has yet to be discovered. To this end, we monitored the relationship between subcellular localization of Fht1p and its flocculation or heat tolerance function using newly developed expression vectors with a recombinant **green fluorescent protein**

(GFP; S65T/S147P) of *Aequorea victoria* added at both the N- and C-terminus of Fht1p. The main fluorescent signal of the GFP tagged with either a wild-type Fht1p or **mutants** which preserve their flocculation function was detected in the nucleus, whereas signals of functionless **mutants** were dispersed to the cytoplasm.

Copyright 2001 National Science Council, ROC and S. Karger AG, Basel

L12 ANSWER 5 OF 9 MEDLINE

DUPLICATE 2

ACCESSION NUMBER: 2001051448 MEDLINE

DOCUMENT NUMBER: 20399378 PubMed ID: 10945281

TITLE: A flexible single-step detection of blotted antigen using a fusion protein between protein A and **green fluorescent protein**

AUTHOR: Aoki T; Miyashita M; Fujino H; Watabe H

CORPORATE SOURCE: Department of Biochemistry, Faculty of Pharmaceutical Sciences, Health Sciences University of Hokkaido, Ishikari-Tobetsu, Japan.. aokit@hoku-iryo-u.ac.jp

SOURCE: BIOSCIENCE, BIOTECHNOLOGY, AND BIOCHEMISTRY, (2000 Jul) 64 (7) 1547-51.

Journal code: BDP. ISSN: 0916-8451.

PUB. COUNTRY: Japan

Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 200001

ENTRY DATE: Entered STN: 20010322

Last Updated on STN: 20010322

Entered Medline: 20001212

AB A **green fluorescent protein**

mutant (S147P GFP) was fused with protein A and expressed in *Escherichia coli*. This fusion protein (PA-GFP147) was used in immunoblotting studies as a new detection system, designated as "flexible single-step detection (FSSD)". In FSSD, the detection of blotted antigen was done in one step, and the antigen-antibody reaction can be monitored by UV-irradiation in real time. The reaction time, therefore, can be flexibly controlled by monitoring the **green** fluorescence.

L12 ANSWER 6 OF 9 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.

09/627383

ACCESSION NUMBER: 2000:369249 BIOSIS
DOCUMENT NUMBER: PREV200000369249
TITLE: S147P green fluorescent protein: A less thermosensitive green fluorescent protein variant.
AUTHOR(S): Kimata, Yukio (1); Ren Lim, Chun; Kohno, Kenji
CORPORATE SOURCE: (1) Research and Education Center for Genetic Information, Nara Institute of Science and Technology, Ikoma, Nara, 630-01 Japan
SOURCE: Conn, P. Michael. Methods in Enzymology, (1999) Vol. 302, pp. 373-378. Methods in Enzymology; Green fluorescent protein. print.
Publisher: Academic Press Inc. 525 B Street, Suite 1900, San Diego, CA, 92101-4495, USA.
ISSN: 0076-6879. ISBN: 0-12-182203-6 (cloth).
DOCUMENT TYPE: Book
LANGUAGE: English
SUMMARY LANGUAGE: English

L12 ANSWER 7 OF 9 MEDLINE DUPLICATE 3
ACCESSION NUMBER: 1999263448 MEDLINE
DOCUMENT NUMBER: 99263448 PubMed ID: 10328944
TITLE: Imaging cells in the developing nervous system with
retrovirus expressing modified green
fluorescent protein.
AUTHOR: Okada A; Lansford R; Weimann J M; Fraser S E;
McConnell S K
CORPORATE SOURCE: Department of Biological Sciences, Stanford
University, Stanford, California, 94305, USA..
amio@leland.stanford.edu
CONTRACT NUMBER: EY08411 (NEI)
MH49176 (NIMH)
NS12151 (NINDS)
+
SOURCE: EXPERIMENTAL NEUROLOGY, (1999 Apr) 156 (2) 394-406.
Journal code: EQF; 0370712. ISSN: 0014-4886.
PUB. COUNTRY: United States
Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199906

ENTRY DATE: Entered STN: 19990614
Last Updated on STN: 19990614
Entered Medline: 19990603

AB To visualize the movements of cells and their processes in developing vertebrates, we constructed replication-incompetent retroviral vectors encoding **green fluorescent protein (GFP)** that can be detected as a single integrated copy per cell. To optimize **GFP** expression, the CMV enhancer and avian beta-actin promoter were incorporated within a retrovirus construct to drive transcription of redshifted (F64L, S65T) and codon-modified **GFP** (EGFP), EGFP tagged with GAP-43 sequences targeting the **GFP** to the cell membrane, or EGFP with additional **mutations** that increase its ability to fold properly at 37 degrees C (**S147P** or **V163A**, **S175G**). We have used these viruses to efficiently mark and follow the developmental progression of a large population of cells in rat neocortex and whole avian embryos. In the chick embryo, the

migration and development of **GFP**-marked neural crest cells were monitored using time-lapse videomicroscopy. In the neocortex, **GFP** clearly delineates the morphology of a variety of neuronal and glial phenotypes. Cells expressing **GFP** display normal dendritic morphologies, and infected cells persist into adulthood. Cortical neurons appear to form normal local axonal and long-distance projections, suggesting that the presence of cytoplasmic or GAP-43-tagged **GFP** does not significantly interfere with normal development.

Copyright 1999 Academic Press.

L12 ANSWER 8 OF 9 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
 ACCESSION NUMBER: 1999137259 EMBASE
 TITLE: **S147P green fluorescent protein**: A less thermosensitive **green fluorescent protein** variant.
 AUTHOR: Kimata Y.; Chu Ren Lim; Kohno K.
 CORPORATE SOURCE: Y. Kimata, Res./Educ. Center for Genetic Info., Nara Institute of Science/Technology, Ikoma, Nara 630-01, Japan
 SOURCE: Methods in Enzymology, (1999) 302/- (373-378).
 COUNTRY: United States
 DOCUMENT TYPE: Journal; Article
 FILE SEGMENT: 029 Clinical Biochemistry
 LANGUAGE: English

L12 ANSWER 9 OF 9 MEDLINE DUPLICATE 4
 ACCESSION NUMBER: 97236282 MEDLINE
 DOCUMENT NUMBER: 97236282 PubMed ID: 9125154
 TITLE: A novel **mutation** which enhances the fluorescence of **green fluorescent protein** at high temperatures.
 AUTHOR: Kimata Y; Iwaki M; Lim C R; Kohno K
 CORPORATE SOURCE: Research and Education Center for Genetic Information, Nara Institute of Science and Technology, Japan.
 SOURCE: BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, (1997 Mar 6) 232 (1) 69-73.
 COUNTRY: United States
 DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
 LANGUAGE: English
 FILE SEGMENT: Priority Journals
 ENTRY MONTH: 199704
 ENTRY DATE: Entered STN: 19970506
 Last Updated on STN: 19980206
 Entered Medline: 19970422

AB **Green fluorescent protein (GFP)**
) from *Aequorea victoria* is widely used as a marker of gene expression and protein localization in living cells from prokaryotes to eukaryotes. However, the total fluorescent signal from wild-type **GFP** is very weak when expressed in cells cultured at 37 degrees C compared to 30 degrees C or below. This characteristic makes **GFP** poorly suited to use as a marker in mammalian cells. Here we describe a new variant of **GFP** which carries a substitution of **Ser147 to Pro (S147P GFP)** and which emits a stronger fluorescent signal than the

09/627383

wild-type **GFP** at high temperature. When **S147P** is combined with the Ser65 to Thr **mutation** (**S65T GFP**), the resulting double **mutant** emits fluorescence which is several-fold stronger than **GFP** with a single S65T modification in both bacterial or mammalian cells. This **S147P mutation** should be useful for constructing new **GFP** variants which stably emit strong fluorescence at a wide range of culturing temperatures.

FILE 'HOME' ENTERED AT 15:47:43 ON 07 JUN 2002